Page last updated: 2024-11-06

mitomycin and Metastase

mitomycin has been researched along with Metastase in 220 studies

Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.

Research Excerpts

ExcerptRelevanceReference
"To determine whether adding bevacizumab, with or without mitomycin, to capecitabine monotherapy improves progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC) in an open-label, three-arm randomized trial."9.14Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. ( Ackland, SP; Broad, A; Chua, Y; Cummins, MM; Cunningham, D; Forgeson, G; Ganju, V; Gebski, VJ; Price, TJ; Robinson, B; Saunders, MP; Simes, RJ; Stockler, MR; Tebbutt, NC; van Hazel, GA; Wilson, K; Zalcberg, JR; Zannino, D, 2010)
"The main objectives of this phase II study were to determine efficacy and safety of the combination of UFT with Leucovorin and mitomycin C in patients with metastatic colorectal cancer."9.11A phase II study of UFT and Leucovorin in combination with mitomycin C in patients with metastatic colorectal cancer. ( Frödin, JE; Glimelius, B; Gyldenkerne, N; Hansen, F; Jakobsen, A; Keldsen, N; Kjaer, M; Pfeiffer, P; Sandberg, E, 2004)
"To compare the efficacy of pegylated liposomal doxorubicin (PLD) with that of a common salvage regimen (comparator) in patients with taxane-refractory advanced breast cancer."9.11Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. ( Alland, L; Erazo, A; Georgoulias, VA; Henderson, IC; Kaufmann, M; Keller, AM; Lluch, A; Mellars, L; Mennel, RG; Nabholtz, JM; Tendler, C; Vogel, CL; von Minckwitz, G, 2004)
"This phase II study assessed the clinical efficacy and tolerability of a combination of mitomycin C, vinblastine and cisplatin in patients with metastatic breast cancer (MBC) previously treated with chemotherapy."9.11Mitomycin C, vinblastine and cisplatin (MVP): an active and well-tolerated salvage regimen for advanced breast cancer. ( Archer, CD; Assersohn, LA; Gregory, RK; Johnston, SR; Mendes, R; Smith, IE; Urruticoechea, A; Verrill, M; Walsh, G, 2005)
"To assess the activity and safety of combined folinic acid (FA), 5-fluorouracil (5-FU) and mitomycin C (MMC) in metastatic breast cancer patients previously treated with at least two chemotherapy regimens."9.10Folinic acid, 5-fluorouracil and mitomycin C in metastatic breast cancer patients previously treated with at least two chemotherapy regimens. ( Correale, P; Fiaschi, AI; Francini, G; Marsili, S; Messinese, S; Petrioli, R; Pozzessere, D; Sabatino, M, 2002)
"Both mitomycin C combination regimens seem to provide an acceptable therapeutic index in patients with fluoropyrimidine/leucovorin-pretreated metastatic colorectal cancer."9.10Randomized phase II study of irinotecan plus mitomycin C vs. oxaliplatin plus mitomycin C in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer. ( Brugger, S; Depisch, D; Fiebiger, W; Kornek, GV; Kovats, E; Lang, F; Raderer, M; Scheithauer, W; Ullrich-Pur, H; Valencak, J, 2002)
"Patients with metastatic breast cancer were randomly assigned to receive as second-line chemotherapy either MMM (mitomycin 8 mg/m2 day 1; mitoxantrone 8 mg/m2 days 1 and 22; methotrexate 35 mg/m2 days 1 and 22) alone or in combination with filgrastim (5 micrograms/kg s."9.08Prophylactic filgrastim (G-CSF) during mitomycin-C, mitoxantrone, and methotrexate (MMM) treatment for metastatic breast cancer. A randomized study. ( Blomqvist, C; Jantunen, I; Kellokumpu-Lehtinen, P; Maiche, A; Muhonen, T; Pertovaara, H; Pyrhönen, S; Voutilainen, L, 1996)
"Mitomycin C (MMC)-vinblastine (VBL) is a regimen that has commonly been used as salvage therapy for advanced breast cancer for many years."9.08Mitomycin C and vinblastine in combination with amifostine in metastatic breast cancer. A feasibility study of the EORTC--Investigational Drug Branch for Breast Cancer (IDBBC). ( Awada, A; Geurs, F; Habboubi, N; Kerger, J; Kusenda, Z; Piccart, MJ; Van Vreckem, A, 1997)
"From December 1988 to February 1991, 112 consecutive patients were submitted to epirubicin + mitomycin C chemotherapy as first-line treatment for advanced breast cancer."9.07Combination chemotherapy with epirubicin and mitomycin C as first-line treatment in advanced breast cancer. ( Algeri, R; Guarnieri, A; Neri, B; Pacini, P; Rinaldini, M; Tucci, E; Valzelli, S, 1994)
"Thirty-seven consecutive patients with advanced and/or metastatic gastric adenocarcinoma received a combination of 5-fluorouracil 600 mg/m2 on days 1, 8, 29, 36; epidoxorubicin 75 mg/m2 i."9.07Combination chemotherapy of 5-fluorouracil, epidoxorubicin and mitomycin C in the palliative treatment of locally advanced and/or metastatic adenocarcinoma of the stomach. ( Bajardi, G; Cannata, G; Cipolla, C; Curto, G; Gebbia, V; Latteri, M; Mastrandrea, G; Pischedda, G; Testa, A; Valenza, R, 1994)
"Twenty-one patients with anthracycline-pretreated advanced breast cancer were treated with mitomycin C plus mitoxantrone (MM), 10 mg/m2, on day 1 of a 28-day cycle."9.07Mitomycin C and mitoxantrone in anthracycline-pretreated advanced breast cancer patients. A phase II study. ( Bianco, AR; Carlomagno, C; De Laurentiis, M; De Placido, S; Del Mastro, L; Gravina, A; Gridelli, C; Pagliarulo, C; Perrone, F, 1994)
"In February 1986 we began a study to test the activity of mitomycin C (12 mg/m2) plus vinblastine (6 mg/m2) on day 1 of a 28-day cycle (MV) as second or third-line chemotherapy for metastatic breast cancer patients."9.07Chemotherapy with mitomycin C and vinblastine in pretreated metastatic breast cancer. ( Bianco, AR; Carlomagno, C; De Laurentiis, M; De Placido, S; Gridelli, C; Nuzzo, F; Pagliarulo, C; Perrone, F; Ruggiero, A, 1993)
"The efficacy and toxicity of navelbine 30 mg/m2 administered intravenously (IV) over 30 minutes every 3 weeks, and mitomycin C 15 mg/m2 administered IV every 6 weeks was assessed in 34 patients with metastatic breast cancer refractory to first-line chemotherapy."9.07Effective second line chemotherapy of advanced breast cancer with navelbine and mitomycin C. ( Depisch, D; Haider, K; Kornek, G; Kwasny, W; Pirker, R; Scheithauer, W; Schenk, T, 1993)
"Seventy-six women with previously treated breast cancer were randomized to receive mitomycin (M) or M plus high-dose oral medroxyprogesterone acetate (MMPA)."9.07A randomized trial of mitomycin-C (M) versus mitomycin-C plus high-dose medroxyprogesterone acetate (MMPA) in the treatment of patients with advanced breast cancer. ( Falkson, CB; Falkson, CI; Falkson, G; Falkson, HC, 1993)
"64 eligible women with previously treated metastatic breast cancer received mitomycin C plus vindesine chemotherapy."9.06Vindesine and mitomycin C in metastatic breast cancer. A Southeastern Cancer Study Group Trial. ( Einhorn, L; Luedke, DW; Luedke, SL; Lyss, AP; Raney, M, 1989)
"Twenty-nine patients with advanced adenocarcinoma of the pancreas were treated with a combination of mitomycin-C, 5-fluorouracil, and adriamycin (MIFA III)."9.05MIFA III (mitomycin-C, 5-fluorouracil, and adriamycin) chemotherapy for advanced adenocarcinoma of the pancreas. ( Cheng, EW; Magill, GB; Sordillo, PP; Sternberg, CN, 1984)
"An overview of the clinical trials where mitomycin has been used in combination with modern compounds in the various settings of metastatic colorectal cancer."8.86Is there a role for mitomycin C in metastatic colorectal cancer? ( Dimou, A; Saif, MW; Syrigos, KN, 2010)
"The aim of this single-arm, prospective, multicenter phase II trial (MiX) was to increase treatment options for women with metastatic breast cancer pretreated with anthracycline and taxane by evaluation of the efficacy and toxicity of the combination of mitomycin C and capecitabine."7.83Mitomycin C and Capecitabine (MiX Trial) for Therapy of Patients with Metastasized, Breast Cancer Pretreated with Anthracycline. ( Almstedt, K; Bayer, CM; Beckmann, MW; Fasching, PA; Hack, CC; Hein, A; Jud, SM; Lux, MP; Rack, B; Rauh, C; Scharl, A; Schrauder, MG, 2016)
"To report on the efficacy and safety of mitomycin-C-capecitabine (MIXE) regimen as salvage chemotherapy regimen for patients with refractory metastatic colorectal cancer."7.79Mitomycin-C and capecitabine (MIXE) as salvage treatment in patients with refractory metastatic colorectal cancer: a retrospective study. ( Brennan, M; Garcon, MC; Kaley, K; Rodriguez, G; Saif, MW, 2013)
"The purpose of our study was to retrospectively evaluate the feasibility, toxicity and impact on overall (OS) and disease-free (DFS) survival of intra-arterial liver perfusion with mitomycin-C (MMC) [hypoxic liver perfusion with MMC (HLPM)] in patients with multifocal liver metastases or with unresectable primary liver tumours."7.77Hypoxic liver perfusion with mitomycin-C for treating multifocal metastases and unresectable primary tumours: a single-centre series of 42 patients. ( Baggiani, A; Bagliani, A; Belli, L; Belloni, P; Bregni, M; Campagnoli, E; Caspani, B; Crocchiolo, R; Ierardi, AM; Motta, F; Setola, E; Tempini, S; Toniolo, D, 2011)
"A combination of mitomycin C, vindesine and melphalan was administered to 33 patients with heavily pretreated refractory breast cancer."7.68Combination chemotherapy with mitomycin C, vindesine and melphalan for refractory metastatic breast cancer. ( D'Alessandro, N; Gebbia, N; Gebbia, V; Palmeri, S; Rausa, L; Russo, A, 1991)
"Twenty-five patients with metastatic breast cancer in progression after prior chemotherapy +/- hormonotherapy were treated with etoposide 50 mg/m2 i."7.67Etoposide and mitomycin-C in pretreated metastatic breast cancer. ( Cellerino, R; Menichetti, ET; Miseria, S; Silva, RR; Torresi, U; Tummarello, D, 1989)
"Mitomycin C (MMC) is rarely used in first-line chemotherapy for advanced breast cancer, although the drug is reported to be active."7.67Mitomycin C is an inactive drug in the third-line treatment of hormone and chemotherapy refractory breast cancer. ( Dees, A; Stoter, G; van Putten, WL; Verweij, J, 1987)
"Forty-nine women with progressive metastatic breast cancer, extensively pretreated, received mitomycin C 12 mg/m2 and vinblastine 6 mg/m2 intravenously every 3 weeks."7.67Mitomycin C and vinblastine in the treatment of advanced breast cancer. ( Knight, RK; Radford, JA; Rubens, RD, 1985)
"Twenty-five patients with metastatic breast cancer who had failed with combination chemotherapies including adriamycin were treated with a combination of mitomycin C, methotrexate, and vincristine (MMV)."7.66[Combination chemotherapy with mitomycin C, methotrexate, and vincristine (MMV) for metastatic breast cancer refractory to adriamycin]. ( Hamada, Y; Kanda, K; Nomura, Y; Saeki, K; Tashiro, H, 1983)
"Fifteen patients with metastatic breast cancer previously treated with chemotherapy were treated with a regimen consisting of vincristine, Adriamycin, and mitomycin."7.66Vincristine, adriamycin, and mitomycin (VAM) therapy for previously treated breast cancer. A preliminary report. ( Oster, MW; Park, Y, 1983)
"Overall, 77."6.72Capecitabine and mitomycin C is an effective combination for anthracycline- and taxane-resistant metastatic breast cancer. ( Burattini, L; La Cesa, A; Marcucci, F; Massacesi, C; Pilone, A; Rocchi, MB; Santini, D; Tonini, G; Zepponi, L, 2006)
"Two hundred ten patients with primary breast cancer (T1-T4, N0, N1-2) were randomised to receive treatment with neoadjuvant chemoendocrine therapy or conventional post-operative chemoendocrine therapy."6.70Estrogen-receptor-directed neoadjuvant therapy for breast cancer: results of a randomised trial using formestane and methotrexate, mitozantrone and mitomycin C (MMM) chemotherapy. ( Coombes, RC; Ford, HT; Gazet, JC; Gray, R; Lowndes, S; Makinde, V; McConkey, C; Quilliam, J; Sutcliffe, R, 2001)
"Although hepatic metastases were detected, total gastrectomy was initially performed for hemorrhage control."5.40[A case of gastric carcinosarcoma treated with surgical resection and irinotecan and mitomycin C combination therapy]. ( Abe, H; Ishibashi, H; Ishigaki, K; Itobayashi, E; Iwai, Y; Katagiri, T; Komata, S; Kubota, M; Matsushima, T; Miyakawa, A; Nakamura, A; Sakaguchi, Y; Shimura, H; Shimura, K; Suzuki, Y; Takashina, A; Tamura, T, 2014)
"Most patients with breast cancer need anthracycline-based chemotherapy regimens in the adjuvant setting, and an increasing number of them receive taxanes either in this setting or as first-line therapy for metastatic breast cancer (MBC)."5.35Possible use of combination chemotherapy with mitomycin C and methotrexate for metastatic breast cancer pretreated with anthracycline and taxanes. ( Hatake, K; Ito, Y; Iwase, T; Miura, H; Seto, Y; Sugihara, T; Takahashi, S; Tanabe, M; Tokudome, N, 2009)
"Fifty-seven patients with metastatic breast carcinoma have been treated with mitomycin C (10 mg/m2 IV 6-weekly), melphalan (6 mg/m2 PO X 3 days, 3-weekly), and methotrexate (35 mg/m2 IV 3-weekly) to assess the efficacy and toxicity of this regimen."5.27Mitomycin C, melphalan and methotrexate combination chemotherapy for palliation of disseminated breast cancer. ( Coombes, RC; Ford, HT; Gazet, JC; Perez, DJ; Powles, TJ, 1984)
"Mitomycin C was given to 9 patients as a third-line regimen with resulting 5 NC for 2-4 months."5.27[Sequential treatment of progressive metastatic colorectal cancer with 5-fluorouracil/folinic acid, dipyramidole and mitomycin C]. ( Farroukh, R; Gerlach, D; Hoffmann, W; Kress, M; Migeod, F; Seeber, S, 1988)
"Patients with high-grade soft tissue sarcomas were treated with 2 cycles of ifosfamide, mitomycin, doxorubicin, and cisplatin plus GM-CSF subcutaneous followed by 45 Gy irradiation with concurrent 2 cycles of mitomycin, doxorubicin, and cisplatin followed by surgery +/- intraoperative radiation or brachytherapy."5.22Chemotherapy, Irradiation, and Surgery for Function-preserving Curative Therapy of Primary Extremity Soft Tissue Sarcomas: Initial Treatment With I-MAP and Inhalation GM-CSF During Preoperative Irradiation and Postoperatively. ( Haddock, M; Mahoney, M; Maples, W; Markovic, SN; O'Connor, MI; Okuno, S; Petersen, I; Shives, T; Sim, F, 2016)
"To determine whether adding bevacizumab, with or without mitomycin, to capecitabine monotherapy improves progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC) in an open-label, three-arm randomized trial."5.14Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. ( Ackland, SP; Broad, A; Chua, Y; Cummins, MM; Cunningham, D; Forgeson, G; Ganju, V; Gebski, VJ; Price, TJ; Robinson, B; Saunders, MP; Simes, RJ; Stockler, MR; Tebbutt, NC; van Hazel, GA; Wilson, K; Zalcberg, JR; Zannino, D, 2010)
"The main objectives of this phase II study were to determine efficacy and safety of the combination of UFT with Leucovorin and mitomycin C in patients with metastatic colorectal cancer."5.11A phase II study of UFT and Leucovorin in combination with mitomycin C in patients with metastatic colorectal cancer. ( Frödin, JE; Glimelius, B; Gyldenkerne, N; Hansen, F; Jakobsen, A; Keldsen, N; Kjaer, M; Pfeiffer, P; Sandberg, E, 2004)
"To compare the efficacy of pegylated liposomal doxorubicin (PLD) with that of a common salvage regimen (comparator) in patients with taxane-refractory advanced breast cancer."5.11Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. ( Alland, L; Erazo, A; Georgoulias, VA; Henderson, IC; Kaufmann, M; Keller, AM; Lluch, A; Mellars, L; Mennel, RG; Nabholtz, JM; Tendler, C; Vogel, CL; von Minckwitz, G, 2004)
"This phase II study assessed the clinical efficacy and tolerability of a combination of mitomycin C, vinblastine and cisplatin in patients with metastatic breast cancer (MBC) previously treated with chemotherapy."5.11Mitomycin C, vinblastine and cisplatin (MVP): an active and well-tolerated salvage regimen for advanced breast cancer. ( Archer, CD; Assersohn, LA; Gregory, RK; Johnston, SR; Mendes, R; Smith, IE; Urruticoechea, A; Verrill, M; Walsh, G, 2005)
"To assess the activity and safety of combined folinic acid (FA), 5-fluorouracil (5-FU) and mitomycin C (MMC) in metastatic breast cancer patients previously treated with at least two chemotherapy regimens."5.10Folinic acid, 5-fluorouracil and mitomycin C in metastatic breast cancer patients previously treated with at least two chemotherapy regimens. ( Correale, P; Fiaschi, AI; Francini, G; Marsili, S; Messinese, S; Petrioli, R; Pozzessere, D; Sabatino, M, 2002)
"Both mitomycin C combination regimens seem to provide an acceptable therapeutic index in patients with fluoropyrimidine/leucovorin-pretreated metastatic colorectal cancer."5.10Randomized phase II study of irinotecan plus mitomycin C vs. oxaliplatin plus mitomycin C in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer. ( Brugger, S; Depisch, D; Fiebiger, W; Kornek, GV; Kovats, E; Lang, F; Raderer, M; Scheithauer, W; Ullrich-Pur, H; Valencak, J, 2002)
"In a randomized trial, the authors evaluated the possible adjuvant activity of intraportal chemotherapy (with 5-fluorouracil 500 mg/m2/day in continuous infusion for 7 days and mitomycin C 10 mg/m2 at day 7) administered after surgery to half of the patients who underwent a full resection for Dukes B2 or C colorectal cancer."5.09Adjuvant intraportal chemotherapy for Dukes B2 and C colorectal cancer also receiving systemic treatment: results of a multicenter randomized trial. Groupe Régional d'Etude du Cancer Colo-Rectal (Belgium). ( Beauduin, M; Brohée, D; Bury, J; Focan, C; Herman, ML; Lecomte, M; Vindevoghel, A, 2000)
"Patients with metastatic breast cancer were randomly assigned to receive as second-line chemotherapy either MMM (mitomycin 8 mg/m2 day 1; mitoxantrone 8 mg/m2 days 1 and 22; methotrexate 35 mg/m2 days 1 and 22) alone or in combination with filgrastim (5 micrograms/kg s."5.08Prophylactic filgrastim (G-CSF) during mitomycin-C, mitoxantrone, and methotrexate (MMM) treatment for metastatic breast cancer. A randomized study. ( Blomqvist, C; Jantunen, I; Kellokumpu-Lehtinen, P; Maiche, A; Muhonen, T; Pertovaara, H; Pyrhönen, S; Voutilainen, L, 1996)
"Between 1985 and 1988, the effect of using ftorafur (FT) or PSK (an immunotherapy agent) in combination with the conventional postoperative adjuvant therapy using mitomycin (MMC) plus tamoxifen (TAM) was assessed in stage II, oestrogen receptor-positive (ER+) breast cancer patients."5.08Postoperative adjuvant randomised trial comparing chemoendocrine therapy, chemotherapy and immunotherapy for patients with stage II breast cancer: 5-year results from the Nishinihon Cooperative Study Group of Adjuvant Chemoendocrine Therapy for Breast Can ( Dohi, K; Monden, Y; Morimoto, T; Nomura, Y; Ogawa, M; Ogawa, N; Orita, K; Sugimachi, K; Toge, T, 1996)
"Mitomycin C (MMC)-vinblastine (VBL) is a regimen that has commonly been used as salvage therapy for advanced breast cancer for many years."5.08Mitomycin C and vinblastine in combination with amifostine in metastatic breast cancer. A feasibility study of the EORTC--Investigational Drug Branch for Breast Cancer (IDBBC). ( Awada, A; Geurs, F; Habboubi, N; Kerger, J; Kusenda, Z; Piccart, MJ; Van Vreckem, A, 1997)
"From December 1988 to February 1991, 112 consecutive patients were submitted to epirubicin + mitomycin C chemotherapy as first-line treatment for advanced breast cancer."5.07Combination chemotherapy with epirubicin and mitomycin C as first-line treatment in advanced breast cancer. ( Algeri, R; Guarnieri, A; Neri, B; Pacini, P; Rinaldini, M; Tucci, E; Valzelli, S, 1994)
"Thirty-seven consecutive patients with advanced and/or metastatic gastric adenocarcinoma received a combination of 5-fluorouracil 600 mg/m2 on days 1, 8, 29, 36; epidoxorubicin 75 mg/m2 i."5.07Combination chemotherapy of 5-fluorouracil, epidoxorubicin and mitomycin C in the palliative treatment of locally advanced and/or metastatic adenocarcinoma of the stomach. ( Bajardi, G; Cannata, G; Cipolla, C; Curto, G; Gebbia, V; Latteri, M; Mastrandrea, G; Pischedda, G; Testa, A; Valenza, R, 1994)
"Twenty-one patients with anthracycline-pretreated advanced breast cancer were treated with mitomycin C plus mitoxantrone (MM), 10 mg/m2, on day 1 of a 28-day cycle."5.07Mitomycin C and mitoxantrone in anthracycline-pretreated advanced breast cancer patients. A phase II study. ( Bianco, AR; Carlomagno, C; De Laurentiis, M; De Placido, S; Del Mastro, L; Gravina, A; Gridelli, C; Pagliarulo, C; Perrone, F, 1994)
"In February 1986 we began a study to test the activity of mitomycin C (12 mg/m2) plus vinblastine (6 mg/m2) on day 1 of a 28-day cycle (MV) as second or third-line chemotherapy for metastatic breast cancer patients."5.07Chemotherapy with mitomycin C and vinblastine in pretreated metastatic breast cancer. ( Bianco, AR; Carlomagno, C; De Laurentiis, M; De Placido, S; Gridelli, C; Nuzzo, F; Pagliarulo, C; Perrone, F; Ruggiero, A, 1993)
"The efficacy and toxicity of navelbine 30 mg/m2 administered intravenously (IV) over 30 minutes every 3 weeks, and mitomycin C 15 mg/m2 administered IV every 6 weeks was assessed in 34 patients with metastatic breast cancer refractory to first-line chemotherapy."5.07Effective second line chemotherapy of advanced breast cancer with navelbine and mitomycin C. ( Depisch, D; Haider, K; Kornek, G; Kwasny, W; Pirker, R; Scheithauer, W; Schenk, T, 1993)
"Seventy-six women with previously treated breast cancer were randomized to receive mitomycin (M) or M plus high-dose oral medroxyprogesterone acetate (MMPA)."5.07A randomized trial of mitomycin-C (M) versus mitomycin-C plus high-dose medroxyprogesterone acetate (MMPA) in the treatment of patients with advanced breast cancer. ( Falkson, CB; Falkson, CI; Falkson, G; Falkson, HC, 1993)
"64 eligible women with previously treated metastatic breast cancer received mitomycin C plus vindesine chemotherapy."5.06Vindesine and mitomycin C in metastatic breast cancer. A Southeastern Cancer Study Group Trial. ( Einhorn, L; Luedke, DW; Luedke, SL; Lyss, AP; Raney, M, 1989)
"Twenty-nine patients with advanced adenocarcinoma of the pancreas were treated with a combination of mitomycin-C, 5-fluorouracil, and adriamycin (MIFA III)."5.05MIFA III (mitomycin-C, 5-fluorouracil, and adriamycin) chemotherapy for advanced adenocarcinoma of the pancreas. ( Cheng, EW; Magill, GB; Sordillo, PP; Sternberg, CN, 1984)
"The Georgetown University Hospital experience in the treatment of advanced breast cancer using either a combination of doxorubicin (adriamycin) and vincristine (AV) or adriamycin and mitomycin-C (AM) is presented."5.05Treatment of advanced breast cancer with two doxorubicin-containing regimens. ( Byrne, PJ; Harris, MA; Oishi, S; Schein, PS; Schlesinger, C; Smith, FP; Ueno, W, 1984)
"An overview of the clinical trials where mitomycin has been used in combination with modern compounds in the various settings of metastatic colorectal cancer."4.86Is there a role for mitomycin C in metastatic colorectal cancer? ( Dimou, A; Saif, MW; Syrigos, KN, 2010)
" Chemotherapy with fluorouracil (5FU) plus leucovorin remains a standard in the treatment of patients with metastatic colorectal cancer."4.80[Irinotecan in combination for colon cancer]. ( André, T; de Gramond, A; Ducreux, M; Gil-Delgado, M; Khayat, D; Ychou, M, 1998)
"The aim of this single-arm, prospective, multicenter phase II trial (MiX) was to increase treatment options for women with metastatic breast cancer pretreated with anthracycline and taxane by evaluation of the efficacy and toxicity of the combination of mitomycin C and capecitabine."3.83Mitomycin C and Capecitabine (MiX Trial) for Therapy of Patients with Metastasized, Breast Cancer Pretreated with Anthracycline. ( Almstedt, K; Bayer, CM; Beckmann, MW; Fasching, PA; Hack, CC; Hein, A; Jud, SM; Lux, MP; Rack, B; Rauh, C; Scharl, A; Schrauder, MG, 2016)
"To report on the efficacy and safety of mitomycin-C-capecitabine (MIXE) regimen as salvage chemotherapy regimen for patients with refractory metastatic colorectal cancer."3.79Mitomycin-C and capecitabine (MIXE) as salvage treatment in patients with refractory metastatic colorectal cancer: a retrospective study. ( Brennan, M; Garcon, MC; Kaley, K; Rodriguez, G; Saif, MW, 2013)
"The purpose of our study was to retrospectively evaluate the feasibility, toxicity and impact on overall (OS) and disease-free (DFS) survival of intra-arterial liver perfusion with mitomycin-C (MMC) [hypoxic liver perfusion with MMC (HLPM)] in patients with multifocal liver metastases or with unresectable primary liver tumours."3.77Hypoxic liver perfusion with mitomycin-C for treating multifocal metastases and unresectable primary tumours: a single-centre series of 42 patients. ( Baggiani, A; Bagliani, A; Belli, L; Belloni, P; Bregni, M; Campagnoli, E; Caspani, B; Crocchiolo, R; Ierardi, AM; Motta, F; Setola, E; Tempini, S; Toniolo, D, 2011)
"A significant reduction in tumor implantation and port-site metastases was observed in all treatment groups (specific oligopeptides and mitomycin)."3.74Inhibition of tumor implantation after laparoscopy by specific oligopeptides: a novel approach to adjuvant intraperitoneal therapy to prevent tumor implantation in an animal model. ( Fornara, P; Jurczok, A; Schneider, A, 2007)
" Nitrotriazole chemosensitizer in ultralow doses increased the sensitivity of leukemia P388/rn substrain with multiple drug resistance phenotype to mitomycin C during combination therapy."3.72Ultralow doses of various drugs in chemotherapy of experimental tumors. ( Konovalova, NP, 2003)
"A combination of mitomycin C, vindesine and melphalan was administered to 33 patients with heavily pretreated refractory breast cancer."3.68Combination chemotherapy with mitomycin C, vindesine and melphalan for refractory metastatic breast cancer. ( D'Alessandro, N; Gebbia, N; Gebbia, V; Palmeri, S; Rausa, L; Russo, A, 1991)
"21 patients with metastatic breast cancer, refractory to conventional agents, were treated with a combination of BCNU, vincristine, mitomycin-C and prednisone given every 4 weeks."3.67Combination chemotherapy with BCNU, vincristine, mitomycin-C and prednisone in refractory breast carcinoma. A pilot study. ( Anderson, P; DiBella, NJ; Fink, K; Garfield, D; Murphy, J; Speer, J, 1984)
"Hexamethylmelamine, mitomycin C and 5-fluorouracil infusion (HexMF) achieved a median survival of 9 months for the 45 patients with either metastatic stage III or unresectable stage II carcinoma of the pancreas."3.67Primary treatment of regional and disseminated pancreatic cancer with hexamethylmelamine, mitomycin C and 5-fluorouracil infusion. ( Bruckner, HW; Butwell, N; Gorbaty, MI; Kalman, J; McKenna, A; Spigelman, M; Storch, J, 1989)
"Twenty-five patients with metastatic breast cancer in progression after prior chemotherapy +/- hormonotherapy were treated with etoposide 50 mg/m2 i."3.67Etoposide and mitomycin-C in pretreated metastatic breast cancer. ( Cellerino, R; Menichetti, ET; Miseria, S; Silva, RR; Torresi, U; Tummarello, D, 1989)
"Of 299 patients who presented with superficial bladder cancer (Ta, T1), 60 were treated by intravesical chemotherapy (Epodyl, methotrexate or mitomycin C)."3.67Superficial bladder cancer: intravesical chemotherapy and tumour progression to muscle invasion or metastases. ( Chisholm, GD; Elton, RA; Hargreave, TB; Newsam, JE; Smith, G, 1986)
"Mitomycin C (MMC) is rarely used in first-line chemotherapy for advanced breast cancer, although the drug is reported to be active."3.67Mitomycin C is an inactive drug in the third-line treatment of hormone and chemotherapy refractory breast cancer. ( Dees, A; Stoter, G; van Putten, WL; Verweij, J, 1987)
"Forty-six patients with recurrent metastatic breast cancer were treated with a combination chemotherapy including doxorubicin and mitomycin C."3.67Possible enhancement of the cardiotoxicity of doxorubicin when combined with mitomycin C. ( Brambilla, MC; Comazzi, R; Genitoni, V; Guindani, A; Lacaita, G; Villani, F; Volonterio, A, 1985)
"Forty-nine women with progressive metastatic breast cancer, extensively pretreated, received mitomycin C 12 mg/m2 and vinblastine 6 mg/m2 intravenously every 3 weeks."3.67Mitomycin C and vinblastine in the treatment of advanced breast cancer. ( Knight, RK; Radford, JA; Rubens, RD, 1985)
" A complete regression of pleural, pulmonary parenchymal, cutaneous, and bone metastases was seen following therapy with 5-fluorouracil, Adriamycin, and mitomycin C."3.66Adenoid cystic carcinoma of the salivary gland. Sustained complete response to chemotherapy. ( Budd, GT; Groppe, CW, 1983)
"Twenty-five patients with metastatic breast cancer who had failed with combination chemotherapies including adriamycin were treated with a combination of mitomycin C, methotrexate, and vincristine (MMV)."3.66[Combination chemotherapy with mitomycin C, methotrexate, and vincristine (MMV) for metastatic breast cancer refractory to adriamycin]. ( Hamada, Y; Kanda, K; Nomura, Y; Saeki, K; Tashiro, H, 1983)
"Logothetis and von Eschenbach first 1981 reported encouraging preliminary results of the DMF regimen (Doxorubicine = Adriamycin, Mitomycin, 5 Fluorouracil) in hormone refractory adenocarcinoma of the prostate."3.66[Treatment of metastasizing prostatic carcinoma with DMF. Presentation of a prospective study]. ( Burk, K; Gropp, C; Rodeck, G, 1983)
"Fifteen patients with metastatic breast cancer previously treated with chemotherapy were treated with a regimen consisting of vincristine, Adriamycin, and mitomycin."3.66Vincristine, adriamycin, and mitomycin (VAM) therapy for previously treated breast cancer. A preliminary report. ( Oster, MW; Park, Y, 1983)
"The incidence of liver metastasis in group A was 34% which was lower than 50% in group B."2.74Effect of multiple-phase regional intra-arterial infusion chemotherapy on patients with resectable pancreatic head adenocarcinoma. ( Fu, DL; Jin, C; Long, J; Ni, QX; Xu, J; Yang, F; Yao, L; Yu, XJ, 2009)
"Although fatigue was the most frequently encountered toxicity safety profiles were generally predictable and manageable."2.73Mitomycin C plus S-1 as second-line therapy in patients with advanced gastric cancer: a noncomparative phase II study. ( Cho, EK; Chung, M; Hong, J; Kim, YS; Lee, JH; Lee, WK; Nam, E; Park, J; Park, SH; Shin, DB, 2008)
"Grade 3/4 neutropenia was observed in 21 % of patients and grade 3/4 febrile neutropenia was seen in only one patient."2.73Salvage chemotherapy with mitomycin C, ifosfamide, and cisplatin (MIC) for previously treated metastatic or recurrent esophageal squamous cell carcinoma. ( Ahn, JS; Ahn, MJ; Hwang, IG; Im, YH; Kang, WK; Lee, SC; Lim, HY; Park, BB; Park, K, 2008)
"Overall, 77."2.72Capecitabine and mitomycin C is an effective combination for anthracycline- and taxane-resistant metastatic breast cancer. ( Burattini, L; La Cesa, A; Marcucci, F; Massacesi, C; Pilone, A; Rocchi, MB; Santini, D; Tonini, G; Zepponi, L, 2006)
"Only 1-year metastasis in the WCA group was 15."2.71[Clinical study on post-operative metastasis prevention of progressive stage of gastric cancer by weichang'an]. ( Shen, KP; Yang, JK; Zhen, J, 2003)
"Progression-free and freedom from metastases rates were 29."2.71Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy coo ( Bamberg, M; Baumann, M; Budach, V; Budach, W; Geismar, D; Grabenbauer, G; Herrmann, T; Hinkelbein, W; Jahnke, K; Lammert, I; Stueben, G; Stuschke, M; Wernecke, KD; Wust, P, 2005)
"Two hundred ten patients with primary breast cancer (T1-T4, N0, N1-2) were randomised to receive treatment with neoadjuvant chemoendocrine therapy or conventional post-operative chemoendocrine therapy."2.70Estrogen-receptor-directed neoadjuvant therapy for breast cancer: results of a randomised trial using formestane and methotrexate, mitozantrone and mitomycin C (MMM) chemotherapy. ( Coombes, RC; Ford, HT; Gazet, JC; Gray, R; Lowndes, S; Makinde, V; McConkey, C; Quilliam, J; Sutcliffe, R, 2001)
"Liver metastasis was the only significant variable in the best subset regression model that predicted good response to MAP (CR and good PR) (P = 0."2.69Induction with mitomycin C, doxorubicin, cisplatin and maintenance with weekly 5-fluorouracil, leucovorin for treatment of metastatic nasopharyngeal carcinoma: a phase II study. ( Hong, RL; Hsu, MM; Ko, JY; Sheen, TS; Ting, LL; Wang, CC, 1999)
"This study was performed to investigate the activity and safety of high dose 5-fluorouracil (5-FU) given as a weekly 24-hour infusion in combination with folinic acid plus mitomycin C in patients with advanced gastric cancer."2.69Weekly 24-hour infusion of high-dose 5-fluorouracil plus folinic acid in combination with mitomycin C for the treatment of advanced gastric cancer. ( Benter, T; Dörken, B; Hohenberger, P; Köhne, CH; Kretzschmar, A; Reichardt, P; Thuss-Patience, PC, 2000)
" Interim analysis did not demonstrate a favorable effect of the combination with this chemotherapeutic agent compared to orchidectomy alone (P = ."2.68Interim results on a randomized trial of mitomycin C in combination with orchidectomy for newly diagnosed metastatic prostate cancer. ( Baert, L; Billiet, I; Casselman, J; Derluyn, J; Paridaens, R; Popelier, G; Van Poppel, H; Vandenbroucke, F; Vanuytsel, L, 1995)
"Vascular invasion and intrahepatic metastasis by hepatocellular carcinoma are important factors predisposing to tumor recurrence."2.67Postoperative adjuvant hepatic arterial infusion of Lipiodol containing anticancer drugs in patients with hepatocellular carcinoma. ( Ii, T; Iyobe, T; Izumi, R; Matsui, O; Miyazaki, I; Nonomura, A; Shimizu, K; Yagi, M, 1994)
"Mitomycin C was used as the anticancer drug and given at the dose of 8mg/m2 per time."2.67[Comparative clinical study in metastatic liver cancer between intra-arterial infusion of mitomycin C alone and intra-arterial infusion of mitomycin C combined with PJ-203 (degradable starch microspheres)]. ( Kondo, M; Nakamura, H; Ogawa, N; Okawa, T; Taguchi, T; Tanikawa, K, 1993)
"Mitomycin C was given at a fixed dose of 20 mg/m2 at the end of the BW12C infusion."2.67Pharmacokinetics of BW12C and mitomycin C, given in combination in a phase 1 study in patients with advanced gastrointestinal cancer. ( Bleehen, NM; Dennis, IF; Ramsay, JR; Workman, P, 1993)
" Preliminary analysis did not demonstrate a favorable effect of the combination with this chemotherapeutic agent compared to orchiectomy alone (p = 0."2.67Mitomycin C in combination with orchiectomy for newly diagnosed metastatic prostate cancer: preliminary results on a randomized trial. ( Baert, L; Billiet, I; Casselman, J; Derluyn, J; Paridaens, R; Popelier, G; van den Broucke, F; Van Poppel, H; van Uytsel, L, 1993)
"Transperitoneal and lymph node metastases were the major causes of treatment failure."2.66Gastric cancer: overview of current therapies. ( Douglass, HO, 1985)
"Although hepatic metastases were detected, total gastrectomy was initially performed for hemorrhage control."1.40[A case of gastric carcinosarcoma treated with surgical resection and irinotecan and mitomycin C combination therapy]. ( Abe, H; Ishibashi, H; Ishigaki, K; Itobayashi, E; Iwai, Y; Katagiri, T; Komata, S; Kubota, M; Matsushima, T; Miyakawa, A; Nakamura, A; Sakaguchi, Y; Shimura, H; Shimura, K; Suzuki, Y; Takashina, A; Tamura, T, 2014)
"Patients had different sources of liver metastasis."1.38Short-term effectiveness of radiochemoembolization for selected hepatic metastases with a combination protocol. ( Akhlaghpoor, S; Amoui, M; Aziz-Ahari, A; Poorbeigi, H; Sheybani, S; Tolooee, S, 2012)
"Among 148 breast cancer samples analyzed by MLPA, four samples harbored intragenic deletions/duplications: Thus, exons 1-2 were deleted in two tumors and exons 21-23 in one tumor, while one sample harbored duplication of exons 18-23."1.37Alterations of the retinoblastoma gene in metastatic breast cancer. ( Berge, EO; Knappskog, S; Lillehaug, JR; Lønning, PE, 2011)
"For patients with advanced breast cancer, overall response rates were 41% for TN tumours and 31% for others (P = 0."1.35Platinum-based chemotherapy in triple-negative breast cancer. ( Arnedos, M; Ashley, S; Johnston, S; Nerurkar, A; Popat, S; Sirohi, B; Smith, IE; Walsh, G, 2008)
"Finally, the growth and metastasis of KGN cells injected subcutaneously (s."1.35Spontaneous transformation of human granulosa cell tumours into an aggressive phenotype: a metastasis model cell line. ( Imai, M; Muraki, M; Saito, H; Seiki, M; Takahashi, Y; Takamatsu, K, 2008)
"Most patients with breast cancer need anthracycline-based chemotherapy regimens in the adjuvant setting, and an increasing number of them receive taxanes either in this setting or as first-line therapy for metastatic breast cancer (MBC)."1.35Possible use of combination chemotherapy with mitomycin C and methotrexate for metastatic breast cancer pretreated with anthracycline and taxanes. ( Hatake, K; Ito, Y; Iwase, T; Miura, H; Seto, Y; Sugihara, T; Takahashi, S; Tanabe, M; Tokudome, N, 2009)
"Generalized metastases showed substantial progression."1.32Lung carcinoma with congenital plantar keratoderma as a variant of Clarke-Howel-Evans syndrome. ( Bonnekoh, B; Franke, I; Gollnick, H; Grundmann, JU; Weisshaar, E, 2003)
"Marimastat seems to be a candidate for the prevention of peritoneal spread of gastric carcinoma."1.31Matrix metalloproteinase inhibitor, marimastat, decreases peritoneal spread of gastric carcinoma in nude mice. ( Fujii, M; Igarashi, N; Kameyama, K; Kimata, M; Kitajima, M; Kubota, T; Kumai, K; Okada, Y; Otani, Y; Wada, N; Yokoyama, T; Yoshimizu, N, 2002)
"IHCP combined with aggressive surgery was performed in 48 gastric carcinoma patients with peritoneal carcinomatosis; 18 gastric carcinoma patients with peritoneal carcinomatosis serving as controls were treated with surgery alone."1.30Improved mortality rate of gastric carcinoma patients with peritoneal carcinomatosis treated with intraperitoneal hyperthermic chemoperfusion combined with surgery. ( Fujimoto, S; Isawa, E; Kobayashi, K; Mutou, T; Ohkubo, H; Sumida, M; Takahashi, M; Toyosawa, T, 1997)
"The recurrent tumors are suggested to be sensitive to the agents as follows: locally recurrent solid tumors, 5-FU; distantly recurrent solid tumors, 5-FU and CDDP; locally recurrent effusion, CDDP; distantly recurrent effusion, ADR."1.29Anticancer chemosensitivity changes between the original and recurrent tumors after successful chemotherapy selected according to the sensitivity assay. ( Araya, S; Hayashi, H; Imamura, M; Ishigami, S; Kawabata, K; Masai, Y; Nio, Y; Tamura, K; Tsubono, M, 1995)
"Pancreatic cancer is a disease with essentially no effective treatment."1.29A novel "patient-like" treatment model of human pancreatic cancer constructed using orthotopic transplantation of histologically intact human tumor tissue in nude mice. ( Furukawa, T; Hoffman, RM; Kitajima, M; Kubota, T; Watanabe, M, 1993)
"We have investigated the therapeutic effect of CH-271 fusion polypeptide containing both cell-binding domain (C-274) and heparin-binding domain (H-271) of fibronectin in combination with anticancer drugs such as doxorubicin (DOX) or mitomycin C (MMC) on tumor metastasis of different types of tumors."1.29Antimetastatic effect by anti-adhesion therapy with cell-adhesive peptide of fibronectin in combination with anticancer drugs. ( Azuma, I; Igarashi, Y; Ishizaki, Y; Kato, I; Kobayashi, H; Komazawa, H; Saiki, I; Yoneda, J, 1993)
"Pseudomyxoma peritonei is a rare disease caused by a perforated adenoma of the appendix."1.29Patterns of failure following treatment of pseudomyxoma peritonei of appendiceal origin. ( Sugarbaker, PH; Zoetmulder, FA, 1996)
"SPG also inhibited the pulmonary metastasis of NR-S1 tumor after radiotherapy."1.28Combination therapy of radiation and Sizofiran (SPG) on the tumor growth and metastasis on squamous-cell carcinoma NR-S1 in syngeneic C3H/He mice. ( Amemiya, K; Arika, T; Nomoto, K, 1992)
"Tegafur p."1.28Alternating chemotherapy in advanced gastric cancer. A phase II study. ( Barón-Saura, JM; Berrocal, A; Feliu, J; Girón, CG; González-Baron, M, 1991)
"For seventy two patients with liver metastasis, radical surgery with removal of liver metastatic lesions post removed intra arterial infusion therapy (5FU,MMC) was carried out and the resulting 5-year survival rate was 40% for patients with H1 liver metastasis."1.28[Surgery for far-advanced colorectal cancer--extension of surgical indication and its results]. ( Hojo, K, 1989)
" On the other hand, results from isolated limb perfusion for satellitosis and in-transit metastasis suggest distinct dose-response correlations with tumoricidal properties of appropriate antineoplastic agents."1.28[Systemically administered regional tumor therapy. Regional hemi-body chemotherapy of metastatic malignant melanoma--an experimental therapy concept]. ( Aigner, KR; Link, KH; Müller, H; Voigt, H; Walther, H, 1989)
"Twelve of the patients had primary hepatocellular carcinoma and six had metastatic liver carcinoma originating from an unknown primary site."1.27Hepatic arterial chemotherapy and occlusion for palliation of primary hepatocellular and unknown primary neoplasms in the liver. ( Benjamin, RS; Chuang, VP; Fuqua, R; Mavligit, GM; Patt, YZ; Wallace, S, 1983)
"Fifty-seven patients with metastatic breast carcinoma have been treated with mitomycin C (10 mg/m2 IV 6-weekly), melphalan (6 mg/m2 PO X 3 days, 3-weekly), and methotrexate (35 mg/m2 IV 3-weekly) to assess the efficacy and toxicity of this regimen."1.27Mitomycin C, melphalan and methotrexate combination chemotherapy for palliation of disseminated breast cancer. ( Coombes, RC; Ford, HT; Gazet, JC; Perez, DJ; Powles, TJ, 1984)
"Especially in liver metastasis of the breast cancer, MMC-m."1.27[Comparison between continuous arterial infusion chemotherapy and mitomycin C microcapsule administration in primary and metastatic liver cancer]. ( Itoh, J; Katoh, T; Nakagawa, H; Sasaki, H; Takahashi, T, 1983)
"Of 55 patients with esophageal squamous cell carcinoma, 30 with localized disease were treated with a combined modality for curative intent."1.27Combined modality therapy for esophageal squamous cell carcinoma. ( Asfaw, I; Franklin, R; Hoschner, J; Loh, J; Miller, P; Rosenberg, J; Steiger, Z; Vaishampayan, G, 1983)
"She died from general metastasis seven months after the radical mastectomy in spite of adjuvant immunochemotherapy."1.27[A case of bilateral metastatic breast carcinoma from gastric carcinoma]. ( Hanamura, N; Iida, F; Kasuga, Y; Katsuyama, T; Oota, H; Senga, O; Tsuchiya, S, 1986)
" Based on the observed objective tumor response rate and median patient survival, further studies of these drugs in combination for the treatment of advanced gastric cancer are indicated."1.27Phase II clinical trial of triazinate in combination with mitomycin C for patients with advanced gastric cancer. ( Hahn, RG; Moertel, CG; O'Connell, MJ; Schutt, AJ, 1987)
"In the amputation system of the same metastasis model at a dose of 4 mg/kg/d i."1.27A novel antitumor cyclic hexapeptide (RA-700) obtained from Rubiae radix. ( Hamanaka, T; Kawahara, K; Ohgoshi, M; Tsukagoshi, S; Tsuruo, T; Yamakawa, K, 1987)
"Three metastatic variants, BL6 (high metastasis), F1 (nonmalignant) and F10 (intermediate malignancy) of the B16 murine melanoma, and a pulmonary metastatic line BL6-ML8 of the BL6 primary tumour have been examined for spontaneous sister chromatid exchange (SCE)."1.27Spontaneous sister chromatid exchange in metastatic variants of the murine B16 melanoma and human astrocytomas in culture. ( Hunt, G; Lakshmi, MS; Sherbet, GV, 1988)
"Mitomycin C was given to 9 patients as a third-line regimen with resulting 5 NC for 2-4 months."1.27[Sequential treatment of progressive metastatic colorectal cancer with 5-fluorouracil/folinic acid, dipyramidole and mitomycin C]. ( Farroukh, R; Gerlach, D; Hoffmann, W; Kress, M; Migeod, F; Seeber, S, 1988)
"The dominant location of metastasis was the liver in 21 pts (48."1.27Chemotherapy of advanced gastric cancer: a study of 43 consecutive cases treated with fluorouracil, adriamycin and mitomycin C (FAM). ( Amadori, D; Amadori, M; Biserni, R; Bonaguri, C; Faedi, M; Gentilini, P; Ravaioli, A; Ridolfi, R, 1986)
"After treatment, the incidence of lung metastasis was analyzed in LLC-inoculated mice, and the presence or absence of metastasis in affiliated lymph nodes was determined in mouse ascites hepatoma 134-inoculated mice."1.27Effects of total-body hyperthermia on metastases from experimental mouse tumors. ( Koga, S; Maeta, M; Oda, M, 1985)
"Nine patients with advanced cervical cancer were treated with a combination chemotherapy (MVP) consisting of mitomycin C 8 mg/m2 i."1.27[A combination chemotherapy using mitomycin C, vincristine and cisplatin (MVP) for advanced cervical cancer]. ( Adachi, K; Horikoshi, N; Ikeda, K; Inagaki, J; Inoue, K; Nakada, H; Ogawa, M; Tada, A; Usui, N; Yamazaki, H, 1985)

Research

Studies (220)

TimeframeStudies, this research(%)All Research%
pre-199090 (40.91)18.7374
1990's60 (27.27)18.2507
2000's44 (20.00)29.6817
2010's23 (10.45)24.3611
2020's3 (1.36)2.80

Authors

AuthorsStudies
Parikh, MS1
Johnson, P1
Romanes, JP1
Freitag, HE1
Spring, ME1
Garcia-Henriquez, N1
Monson, JRT1
Woeste, MR1
Philips, P1
Egger, ME1
Scoggins, CR1
McMasters, KM1
Martin, RCG1
Chen, L1
Chen, Q1
Wu, Y1
Zhu, M1
Hu, J1
Zhuang, Z1
Moiseenko, AV1
Polikarpov, AA1
Tarazov, PG1
Korovina, YV1
Rozengauz, EV1
Shelkoplyas, EN1
Granov, DA1
Saif, MW2
Kaley, K1
Brennan, M1
Garcon, MC1
Rodriguez, G1
Ozdemir, O1
Ozdemir, P1
Veral, A1
Uluer, H1
Ozhan, MH1
Ueda, A1
Hosokawa, A1
Ogawa, K1
Yoshita, H1
Mihara, H1
Ando, T1
Kajiura, S1
Fujinami, H1
Nishikawa, J1
Minemura, M1
Terada, M1
Kobayashi, T2
Horikawa, N1
Yabushita, K1
Note, M1
Sugiyama, T1
Miyakawa, A1
Ishibashi, H2
Takashina, A1
Ishigaki, K1
Iwai, Y1
Abe, H1
Katagiri, T1
Sakaguchi, Y1
Matsushima, T1
Tamura, T1
Komata, S1
Kubota, M1
Suzuki, Y1
Nakamura, A1
Itobayashi, E1
Shimura, H1
Shimura, K1
Okuno, S1
Petersen, I1
Shives, T1
Mahoney, M1
Haddock, M1
Sim, F1
O'Connor, MI1
Markovic, SN1
Maples, W1
Miranda, MB1
Hartmann, JT2
Al-Batran, SE2
Kripp, M1
Gencer, D1
Hochhaus, A1
Hofheinz, RD1
Merx, K1
Bozkurt, O1
Karaca, H1
Ciltas, A1
Kaplan, MA1
Benekli, M1
Sevinc, A1
Demirci, U1
Eren, T1
Kodaz, H1
Isikdogan, A1
Ozkan, M1
Buyukberber, S1
Stec, R1
Bodnar, L1
Smoter, M1
Korniluk, J1
Kuchar, A1
Młot, B1
Szczylik, C1
Weickhardt, AJ1
Williams, DS1
Lee, CK1
Chionh, F1
Simes, J1
Murone, C1
Wilson, K2
Parry, MM1
Asadi, K1
Scott, AM1
Punt, CJ1
Nagtegaal, ID1
Price, TJ2
Mariadason, JM1
Tebbutt, NC2
Schneider, CC1
Archid, R1
Fischer, N1
Bühler, S1
Venturelli, S1
Berger, A1
Burkard, M1
Kirschniak, A1
Bachmann, R1
Königsrainer, A1
Glatzle, J1
Zieker, D1
Belgioia, L1
Vagge, S1
Agnese, D1
Garelli, S1
Murialdo, R1
Fornarini, G1
Chiara, S1
Gallo, F1
Bacigalupo, A1
Corvò, R1
Almstedt, K1
Fasching, PA1
Scharl, A1
Rauh, C1
Rack, B1
Hein, A1
Hack, CC1
Bayer, CM1
Jud, SM1
Schrauder, MG1
Beckmann, MW1
Lux, MP1
Park, SH1
Kim, YS1
Hong, J1
Park, J1
Nam, E1
Cho, EK1
Shin, DB1
Lee, JH2
Lee, WK1
Chung, M1
Sirohi, B1
Arnedos, M1
Popat, S1
Ashley, S2
Nerurkar, A1
Walsh, G2
Johnston, S1
Smith, IE4
Imai, M1
Muraki, M1
Takamatsu, K1
Saito, H1
Seiki, M1
Takahashi, Y1
Tanabe, M1
Ito, Y1
Tokudome, N1
Sugihara, T1
Miura, H1
Takahashi, S1
Seto, Y1
Iwase, T1
Hatake, K1
Jin, C1
Yao, L1
Long, J1
Fu, DL1
Yu, XJ1
Xu, J3
Yang, F1
Ni, QX1
Li, M1
Zhang, J1
Wang, D1
Zhong, B1
Tucker, S1
Lu, C1
Cheng, J1
Cao, C1
Pan, H1
Dimou, A1
Syrigos, KN1
Sun, B1
Yu, KR1
Bhandari, DR1
Jung, JW1
Kang, SK1
Kang, KS1
Gebski, VJ1
Cummins, MM1
Zannino, D1
van Hazel, GA1
Robinson, B1
Broad, A1
Ganju, V1
Ackland, SP1
Forgeson, G1
Cunningham, D1
Saunders, MP1
Stockler, MR1
Chua, Y1
Zalcberg, JR1
Simes, RJ1
Segawa, Y1
Kiura, K1
Takigawa, N1
Kamei, H1
Harita, S1
Hiraki, S1
Watanabe, Y1
Sugimoto, K1
Shibayama, T1
Yonei, T1
Ueoka, H1
Takemoto, M1
Kanazawa, S1
Takata, I1
Nogami, N1
Hotta, K1
Hiraki, A1
Tabata, M1
Matsuo, K1
Tanimoto, M1
Güntner, M1
Pauligk, C1
Scholz, M1
Chen, R1
Beiss, B1
Stopatschinskaja, S1
Lerbs, W1
Harbeck, N1
Jäger, E1
Berge, EO1
Knappskog, S1
Lillehaug, JR1
Lønning, PE1
Vrdoljak, E1
Boban, M1
Omrcen, T1
Hrepic, D1
Fridl-Vidas, V1
Boskovic, L1
Bagliani, A1
Baggiani, A1
Ierardi, AM1
Caspani, B1
Motta, F1
Toniolo, D1
Belloni, P1
Setola, E1
Campagnoli, E1
Tempini, S1
Crocchiolo, R1
Bregni, M1
Belli, L1
Akhlaghpoor, S1
Aziz-Ahari, A1
Amoui, M1
Tolooee, S1
Poorbeigi, H1
Sheybani, S1
Gunderson, LL1
Winter, KA1
Ajani, JA1
Pedersen, JE1
Moughan, J1
Benson, AB1
Thomas, CR1
Mayer, RJ1
Haddock, MG1
Rich, TA1
Willett, CG1
Kimata, M2
Otani, Y3
Kubota, T4
Igarashi, N3
Yokoyama, T1
Wada, N1
Yoshimizu, N1
Fujii, M1
Kameyama, K1
Okada, Y1
Kumai, K2
Kitajima, M4
Francini, G1
Petrioli, R1
Messinese, S1
Pozzessere, D1
Marsili, S1
Correale, P1
Sabatino, M1
Fiaschi, AI1
Shamash, J2
Steele, JP1
Wilson, P2
Nystrom, M1
Ansell, W2
Oliver, RT1
Grundmann, JU1
Weisshaar, E1
Franke, I1
Bonnekoh, B1
Gollnick, H1
Konovalova, NP1
KOOP, CE1
FUJIMORI, M1
SAKAUCHI, G1
IZUO, M1
ABE, C1
MORITA, S1
NASHIMOTO, T1
ISHIKAWA, S1
SADMITSU, H1
KAWAI, T1
IMANAGA, H1
ITO, I1
HATTORI, T1
KOYAMA, Y2
OBOSHI, S1
FUJITA, H1
KANAGAMI, H1
NIITANI, K1
KATSURA, T1
HANDLER, AH1
SARRIS, TG1
WILLS, C1
KONDO, T1
UENO, K1
KOIZUMI, A2
YOSHIDA, K1
TAKAHASHI, T4
YAMAGUCHI, I1
MAJIMA, S1
HIRONO, I1
KOJIMA, K1
KACHI, H1
OHASHI, A1
SASAOKA, I1
Yang, JK1
Zhen, J1
Shen, KP1
Gyldenkerne, N1
Glimelius, B1
Frödin, JE1
Kjaer, M1
Pfeiffer, P2
Hansen, F1
Keldsen, N1
Sandberg, E1
Jakobsen, A1
Sigounas, G1
Sallah, S1
Sigounas, VY1
Keller, AM1
Mennel, RG1
Georgoulias, VA1
Nabholtz, JM2
Erazo, A1
Lluch, A1
Vogel, CL1
Kaufmann, M1
von Minckwitz, G1
Henderson, IC1
Mellars, L1
Alland, L1
Tendler, C1
Urruticoechea, A1
Archer, CD1
Assersohn, LA1
Gregory, RK2
Verrill, M1
Mendes, R1
Johnston, SR1
Gibson, MK1
Holcroft, CA1
Kvols, LK1
Haller, D1
Budach, V1
Stuschke, M1
Budach, W1
Baumann, M1
Geismar, D1
Grabenbauer, G1
Lammert, I1
Jahnke, K1
Stueben, G1
Herrmann, T1
Bamberg, M1
Wust, P1
Hinkelbein, W1
Wernecke, KD1
Powles, T1
Oliver, T1
Pelz, JO1
Doerfer, J1
Hohenberger, W1
Meyer, T1
Polyzos, A1
Koulentianos, E1
Tzianoumis, L1
Sfikakis, P1
Alexopoulos, A1
Rigatos, G1
Stavrinidis, E1
Stavrakakis, J1
Scartsilas, C1
Papacharalambous, A1
Alliot, C1
Cok, G1
Göksel, T1
Soyer, S1
Atil, H1
Güzelant, A1
Aysan, T1
Massacesi, C1
La Cesa, A1
Marcucci, F1
Pilone, A1
Rocchi, MB1
Zepponi, L1
Santini, D1
Tonini, G1
Burattini, L1
Jurczok, A1
Schneider, A1
Fornara, P1
Rahman-Roblick, R1
Roblick, UJ1
Hellman, U1
Conrotto, P1
Liu, T1
Becker, S1
Hirschberg, D1
Jörnvall, H1
Auer, G1
Wiman, KG1
Liedberg, F1
Vormittag, L1
Kornek, GV2
Gruhsmann, B1
Lenauer, A1
Föger, A1
Depisch, D3
Lang, F2
Scheithauer, W3
Park, BB1
Im, YH1
Hwang, IG1
Lee, SC1
Ahn, JS1
Ahn, MJ1
Lim, HY1
Kang, WK1
Park, K1
Mrozek, E1
Kolesar, J1
Young, D1
Allen, J1
Villalona-Calero, M1
Shapiro, CL1
Chalasani, P1
Kurtin, S1
Dragovich, T1
Patt, YZ1
Chuang, VP1
Wallace, S1
Benjamin, RS1
Fuqua, R1
Mavligit, GM1
Tanigawa, N1
Mizuno, Y1
Hashimura, T1
Honda, K1
Satomura, K1
Hikasa, Y1
Niwa, O1
Sugahara, T1
Yoshida, O1
Kern, DH1
Kelsen, D1
Perez, DJ1
Powles, TJ4
Gazet, JC2
Ford, HT2
Coombes, RC3
Budd, GT1
Groppe, CW1
Itoh, J1
Nakagawa, H1
Sasaki, H1
Katoh, T1
Sternberg, CN1
Magill, GB1
Sordillo, PP1
Cheng, EW1
Franklin, R1
Steiger, Z2
Vaishampayan, G1
Asfaw, I2
Rosenberg, J1
Loh, J1
Hoschner, J1
Miller, P1
Tannock, IF1
Alcobendas, F1
Milla, A1
Estape, J1
Curto, J1
Pera, C1
Perry, DJ1
Tanaka, T1
Iguchi, K1
Hashimoto, I1
Nomura, Y2
Kanda, K1
Tashiro, H1
Hamada, Y1
Saeki, K1
Burk, K2
Gropp, C2
Rodeck, G1
Harris, MA1
Byrne, PJ1
Smith, FP1
Ueno, W1
Schlesinger, C1
Oishi, S1
Schein, PS1
Ozaki, A1
Saijo, N1
Beppu, Y1
Takahashi, K1
Shimizu, E1
Hoshi, A1
DiBella, NJ1
Garfield, D1
Fink, K1
Anderson, P1
Speer, J1
Murphy, J1
Beck, TM2
Curtis, PW1
Woodard, DA2
Hart, NE2
Smith, CE2
Orita, K2
Miwa, H1
Yamashita, H1
Kurimoto, M1
Murasawa, K1
Tseng, MH1
Luch, J1
Mittelman, A1
Dennis, JW1
Laferté, S1
Man, MS1
Elliott, BE1
Kerbel, RS1
Chahinian, AP1
Green, G1
Holland, JF1
Ridolfi, R2
Casadei Giunchi, D1
Cortesi, C1
Maltoni, M1
Ravaioli, A2
Amadori, D2
Kasimis, BS2
Moran, EM2
Miller, JB2
Forbes, KA2
Kaneshiro, CA2
Poblet, MT1
Williams, JL1
Konits, PH1
Aisner, J1
van Echo, DA1
Lichtenfeld, K1
Wiernik, PH1
Conroy, JF1
Roda, PI1
Brodsky, I1
Kahn, SB1
Bulova, SI1
Pequignot, E1
van Oosterom, AT1
Hamersma, E1
Engelsman, E1
Kinami, Y1
Konishi, K1
Shinmura, K1
Takada, M1
Sakuma, H1
Nagakawa, T1
Miyazaki, I2
Fujimoto, S2
Miyazaki, M1
Okui, K1
Oster, MW1
Park, Y1
Sengeløv, L1
Nielsen, OS1
Kamby, C1
von der Maase, H1
Pacini, P2
Tucci, E2
Algeri, R2
Rinaldini, M2
Guarnieri, A1
Valzelli, S1
Neri, B2
Gebbia, V2
Testa, A1
Valenza, R1
Latteri, M1
Bajardi, G1
Mastrandrea, G1
Cipolla, C1
Pischedda, G1
Curto, G1
Cannata, G1
Vandenbroucke, F1
Van Poppel, H2
Derluyn, J2
Popelier, G2
Casselman, J2
Billiet, I2
Vanuytsel, L1
Paridaens, R2
Baert, L2
Nio, Y1
Tamura, K1
Tsubono, M1
Kawabata, K1
Masai, Y1
Hayashi, H1
Ishigami, S1
Araya, S1
Imamura, M1
Izumi, R1
Shimizu, K1
Iyobe, T1
Ii, T1
Yagi, M1
Matsui, O1
Nonomura, A1
Perrone, F2
De Placido, S2
Carlomagno, C2
Gravina, A1
De Laurentiis, M2
Del Mastro, L1
Gridelli, C2
Pagliarulo, C2
Bianco, AR2
Taguchi, T2
Tanikawa, K2
Sano, K1
Nakamura, H2
Okawa, T2
Miura, T1
Ogawa, N3
Kondo, M1
Nuzzo, F1
Ruggiero, A1
Furukawa, T1
Watanabe, M3
Hoffman, RM1
Allal, A1
Kurtz, JM1
Pipard, G1
Marti, MC1
Miralbell, R1
Popowski, Y1
Egeli, R1
Satou, T1
Kornek, G1
Haider, K1
Kwasny, W1
Schenk, T1
Pirker, R1
Falkson, CI2
Falkson, G2
Falkson, CB2
Falkson, HC2
Brockmann, WP1
Wiegel, T1
Sommer, K1
Steiner, P1
Hübener, KH1
Dennis, IF1
Ramsay, JR1
Workman, P1
Bleehen, NM1
Saiki, I1
Yoneda, J1
Kobayashi, H1
Igarashi, Y1
Komazawa, H1
Ishizaki, Y1
Kato, I1
Azuma, I1
van den Broucke, F1
van Uytsel, L1
Ozaki, H1
Kinoshita, T1
Kosuge, T1
Yamamoto, J1
Shimada, K1
Inoue, K2
Mukai, K1
Muhonen, T1
Jantunen, I1
Pertovaara, H1
Voutilainen, L1
Maiche, A1
Blomqvist, C1
Pyrhönen, S1
Kellokumpu-Lehtinen, P1
Morimoto, T1
Ogawa, M2
Sugimachi, K1
Toge, T1
Dohi, K1
Monden, Y1
Zoetmulder, FA1
Sugarbaker, PH1
Takahashi, M1
Mutou, T1
Kobayashi, K1
Toyosawa, T1
Isawa, E1
Sumida, M1
Ohkubo, H1
Chan, AK1
Wong, AO1
Langevin, JM1
Jenken, DA1
Khoo, R1
Heine, JA1
Buie, WD1
Johnson, DR1
Hao, W1
Messbarger, L1
Joshi, SS1
Otto, T1
Krege, S1
Otto, B1
Goepel, M1
Rübben, H1
Kusenda, Z1
Kerger, J1
Awada, A1
Geurs, F1
Van Vreckem, A1
Habboubi, N1
Piccart, MJ1
Chang, JC1
Blaszkowsky, L1
Crown, J2
Patiutko, IuI1
Kotel'nikov, AG1
Badalian, KhV1
Sagaĭdak, IV1
Ducreux, M1
Gil-Delgado, M1
André, T1
Ychou, M1
de Gramond, A1
Khayat, D1
Matsuzaki, SW1
Teramoto, T1
Tamaki, K1
Tanzawa, K1
Hong, RL1
Sheen, TS1
Ko, JY1
Hsu, MM1
Wang, CC1
Ting, LL1
Tanner, J1
Dunst, J2
Quietzsch, D1
Daikeler, T1
Kollmannsberger, C1
Mayer, F1
Kanz, L1
Bokemeyer, C1
Juvekar, AS1
Amonkar, AJ1
D'cruz, AK1
Saikaia, T1
Pradhan, S1
Guarneri, A1
Barsanti, G1
Bastiani, P1
Marzano, S1
Fallai, C1
Kretzschmar, A1
Reichardt, P1
Thuss-Patience, PC1
Hohenberger, P1
Benter, T1
Dörken, B1
Köhne, CH1
Focan, C1
Bury, J1
Beauduin, M1
Herman, ML1
Vindevoghel, A1
Brohée, D1
Lecomte, M1
Grumett, SA1
Archer, VR1
Midgley, R1
Mulholland, P1
Nicum, S1
Blewitt, L1
Kerr, DJ1
Gray, R1
McConkey, C1
Sutcliffe, R1
Quilliam, J1
Makinde, V1
Lowndes, S1
Li, N1
van Agthoven, M1
Willemse, P1
Uyl-de Groot, C1
Kato, Y2
Onishi, H2
Machida, Y2
Rixe, O1
Tan, SM1
Cheung, KL1
Willsher, PC1
Blamey, RW1
Chan, SY1
Robertson, JF1
Haensgen, G1
Seitz, JF1
Duffaud, F1
Dahan, L1
Ries, P1
Ville, E1
Laugier, R1
Manziuk, LV1
Artamonova, EV1
Sholokhov, VN1
Strygina, EA1
Brugger, S1
Ullrich-Pur, H1
Valencak, J1
Raderer, M1
Fiebiger, W1
Kovats, E1
Stockler, M1
Raghavan, D1
McCaughan, BC1
Grygiel, J1
McNeil, E1
Gianoutsos, P1
Degardin, M1
Hecquet, B1
Bonneterre, J1
Adenis, A1
Pion, JM1
Demaille, A1
Oguro, Y1
Mizutani, J1
Hiraoka, T1
Yamashita, R1
Miyauchi, Y1
Cold, S1
Rose, C1
Arika, T1
Amemiya, K1
Nomoto, K1
Cunliffe, WJ1
Douglass, HO2
Araújo, CM1
Souhami, L1
Gil, RA1
Carvalho, R1
Garcia, JA1
Froimtchuk, MJ1
Pinto, LH1
Canary, PC1
Rausa, L1
Russo, A1
Gebbia, N1
D'Alessandro, N1
Palmeri, S1
Mitomi, T1
Tsuchiya, S2
Iijima, N1
Aso, K1
Suzuki, K1
Nishiyama, K1
Amano, T1
Murayama, N1
Oka, H1
Yanagawa, M1
Suzuki, S1
Kameda, K1
Nakano, S1
Kinbara, H1
Araki, T1
Sakurai, M1
Hioki, T1
Sugimura, Y1
Tochigi, H1
Fujii, T1
Yokomori, T1
Topham, C1
Glees, J1
Rawson, NS1
Woods, EM1
Feliu, J1
Girón, CG1
González-Baron, M1
Berrocal, A1
Barón-Saura, JM1
Tomita, M1
Ishikawa, H1
Nakagoe, T1
Shimizu, T1
Hirano, T1
Eida, K1
Ishii, T1
Tobinaga, K1
Kotake, Y1
Nogawa, T1
O'Brien, ME1
Bayliss, EJ1
Stewart, ME1
Smyth, JF1
Rodger, A1
Leonard, RC1
Giannone, L1
Brenner, DE1
Jones, HW1
Greco, FA1
Burnett, LS1
Leichman, L1
Herskovic, A1
Leichman, CG1
Lattin, PB1
Tapazoglou, E1
Rosenberg, JC1
Arbulu, A1
Kinzie, J1
Lahousen, M1
Pickel, H1
Tamussino, K1
Alberts, DS1
Kronmal, R1
Baker, LH1
Stock-Novack, DL1
Surwit, EA1
Boutselis, JG1
Hannigan, EV1
Aoki, Y1
Tabuse, Y1
Tanimura, H1
Katsumi, M1
Asae, M1
Ichimiya, G1
Imai, T1
Ooshima, K1
Kakihara, M1
Kashitani, M1
Habr-Gama, A1
da Silva e Sousa Júnior, AH1
Nadalin, W1
Gansl, R1
da Silva, JH1
Pinotti, HW1
Hojo, K1
Queisser, W2
Flechtner, H2
Heim, ME2
Kabelitz, K1
Massner, B1
Edler, L1
Lyss, AP1
Luedke, SL1
Einhorn, L1
Luedke, DW1
Raney, M1
Bruckner, HW1
Kalman, J1
Spigelman, M1
Gorbaty, MI1
Butwell, N1
Storch, J1
McKenna, A1
Menichetti, ET1
Silva, RR1
Tummarello, D1
Miseria, S1
Torresi, U1
Cellerino, R1
Voigt, H1
Aigner, KR1
Link, KH1
Walther, H1
Müller, H1
Crinó, L2
Darwish, S1
Corgna, E1
Meacci, ML1
Di Costanzo, F2
Buzzi, F2
Fornari, G1
Santi, F1
Ballatori, E1
Luccioli, L1
Belpomme, D1
Cour, V1
Gisselbrecht, C1
Le Rol, A1
Mignot, L1
Marty, M1
Godeffroy, W1
Maral, J1
Gori, S1
Tonato, M1
Grignani, F1
Davis, S1
Kasuga, Y1
Senga, O1
Hanamura, N1
Iida, F1
Oota, H1
Katsuyama, T1
Eagan, RT1
Frytak, S1
Richardson, RL1
Creagan, ET1
Nichols, WC1
Smith, G1
Elton, RA1
Chisholm, GD1
Newsam, JE1
Hargreave, TB1
Ahmann, FR2
Pugh, R1
O'Connell, MJ1
Schutt, AJ1
Moertel, CG1
Hahn, RG1
Neumann, R1
Common, H1
Ricken, D1
Erlichman, C1
Rauth, AM1
Battistella, R1
Fine, S1
Henss, H1
Arnold, H1
Fritze, D1
Herrmann, R1
Fritsch, H1
Fritz, M1
Trux, FA1
Cruciani, G1
Tienghi, A1
Molinari, AL1
Fiorentini, G1
Rosti, G1
Turci, D1
Marangolo, M1
Dees, A1
Verweij, J1
van Putten, WL1
Stoter, G1
D'Elia, JA1
Aslani, M1
Schermer, S1
Cloud, L1
Bothe, A1
Dzik, W1
Mohiuddin, M1
Cantor, RJ1
Biermann, W1
Weiss, SM1
Barbot, D1
Rosato, FE1
Hamanaka, T1
Ohgoshi, M1
Kawahara, K1
Yamakawa, K1
Tsuruo, T1
Tsukagoshi, S1
Keymling, M1
Lübke, HJ1
Wörner, W1
Lakshmi, MS1
Hunt, G1
Sherbet, GV1
Migeod, F1
Gerlach, D1
Kress, M1
Hoffmann, W1
Farroukh, R1
Seeber, S1
Kanno, A1
Tanaka, S1
Ito, T1
Ban, K1
Oshita, H1
Fukata, D1
Sakai, N1
Kashizuka, T1
Hatoh, T1
Ruckdeschel, JC2
Finkelstein, DM2
Ettinger, DS2
Creech, RH1
Mason, BA1
Joss, RA1
Vogl, S1
Kris, MG1
Gralla, RJ1
Wertheim, MS1
Kelsen, DP1
O'Connell, JP1
Burke, MT1
Fiore, JJ1
Cibas, IR1
Heelan, RT1
Miller, TP1
Vance, RB1
Rodney, SR1
Faedi, M1
Amadori, M1
Gentilini, P1
Biserni, R1
Bonaguri, C1
Metter, GE1
Oda, M1
Koga, S1
Maeta, M1
Villani, F1
Comazzi, R1
Lacaita, G1
Guindani, A1
Genitoni, V1
Volonterio, A1
Brambilla, MC1
Bocian, RC1
Dray, S1
Ben-Efraim, S1
Mokyr, MB1
de Riese, W1
Löbenau, S1
Radford, JA1
Knight, RK1
Rubens, RD1
Ikeda, K1
Inagaki, J1
Horikoshi, N1
Usui, N1
Nakada, H1
Adachi, K1
Yamazaki, H1
Tada, A1

Clinical Trials (7)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
An Adaptive, Randomized Phase II Trial to Determine Pathologic Complete Response With the Addition of Carboplatin With and Without Veliparib to Standard Chemotherapy in the Neoadjuvant Treatment of Triple-Negative Breast Cancer[NCT01818063]Phase 29 participants (Actual)Interventional2013-04-25Completed
Pembrolizumab + Platinum Doublets Without Radiation for Patients With PD-L1 ≥50% Locally Advanced Non-small Cell Lung Cancer: a Multicenter Prospective Single Arm Phase II Study[NCT04153734]Phase 221 participants (Anticipated)Interventional2019-12-01Not yet recruiting
A Prospective Phase Ⅱ Study of Split-course Chemoradiotherapy For Locally Advanced None-small Cell Lung Cancer[NCT02573506]Phase 299 participants (Actual)Interventional2015-08-31Completed
Split-course Thoracic Radiotherapy Combined With Nab-paclitaxel Plus Nedaplatin for Local Advanced NSCLC With Impaired Baseline Pulmonary Function[NCT04212052]Phase 271 participants (Anticipated)Interventional2019-12-01Active, not recruiting
A Phase II,Randomized Controlled Clinical Trial of Staged Thoracic Radiotherapy Combined With Albumin Bound Paclitaxel and Nedaplatin Twice a Week for Locally Advanced NSCLC[NCT04524299]Phase 2160 participants (Anticipated)Interventional2020-06-01Recruiting
Hypofractionated Radiotherapy Followed by Hypofractionated Boost With Weekly Concurrent Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: A Prospective, Single Arm Phase II Study[NCT03900117]Phase 277 participants (Actual)Interventional2019-03-01Completed
A Phase III Randomized Study of 5-Fluorouracil, Mitomycin-C, and Radiotherapy Versus 5-Fluorouracil, Cisplatin, and Radiotherapy in Carcinoma of the Anal Canal[NCT00003596]Phase 3682 participants (Actual)Interventional1998-10-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Count of Participants That Achieve Pathologic Complete Response (PCR)

PCR is defined as the absence of any residual invasive cancer on hematoxylin and eosin (H&E) evaluation of the resected breast specimen and all sampled ipsilateral lymph nodes. (NCT01818063)
Timeframe: 36 months following surgery

InterventionParticipants (Count of Participants)
Arm 1 (Paclitaxel, Carboplatin)3
Arm 2 (Veliparib, Paclitaxel, Carboplatin)3

Reviews

15 reviews available for mitomycin and Metastase

ArticleYear
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: A Systematic Review.
    Diseases of the colon and rectum, 2022, 01-01, Volume: 65, Issue:1

    Topics: Adult; Antibiotics, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Cytoreduction S

2022
Is there a role for mitomycin C in metastatic colorectal cancer?
    Expert opinion on investigational drugs, 2010, Volume: 19, Issue:6

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neopla

2010
Chemotherapy of esophageal cancer.
    Seminars in oncology, 1984, Volume: 11, Issue:2

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Doxorub

1984
[Mechanism of neoplasm metastasis and treatment strategy].
    Nihon Geka Gakkai zasshi, 1995, Volume: 96, Issue:8

    Topics: Humans; Immunotoxins; Mitomycin; Neoplasm Invasiveness; Neoplasm Metastasis; Peritoneal Neoplasms; S

1995
Treatment of advanced and metastatic pancreatic cancer.
    Frontiers in bioscience : a journal and virtual library, 1998, Nov-01, Volume: 3

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cis

1998
[Ways of improving long-term results of treatment in resectable pancreatic cancer].
    Voprosy onkologii, 1998, Volume: 44, Issue:5

    Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Combined Modality Therapy; Evaluation

1998
[Irinotecan in combination for colon cancer].
    Bulletin du cancer, 1998, Volume: Spec No

    Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; C

1998
Phase III randomized trials of docetaxel in patients with metastatic breast cancer.
    Seminars in oncology, 1999, Volume: 26, Issue:3 Suppl 8

    Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms;

1999
Simultaneous radiochemotherapy in cervical cancer: recommendations for chemotherapy.
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2001, Volume: 177, Issue:12

    Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineop

2001
[A study of VMMC protocol (vindesine, mitoxantrone, mitomycin C) as a salvage chemotherapy in advanced breast cancers].
    Bulletin du cancer, 1992, Volume: 79, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relatio

1992
Cytotoxic treatment of metastatic breast cancer. Which drugs and drug combinations to use?
    Acta oncologica (Stockholm, Sweden), 1992, Volume: 31, Issue:2

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin;

1992
The rationale for early postoperative intraperitoneal chemotherapy for gastric cancer.
    Cancer treatment and research, 1991, Volume: 55

    Topics: Chemotherapy, Adjuvant; Cisplatin; Doxorubicin; Drug Evaluation; Fluorouracil; Humans; Infusions, Pa

1991
Rationale for the intraperitoneal approach to surgical adjuvant chemotherapy of gastric cancer.
    Cancer treatment and research, 1991, Volume: 55

    Topics: Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Fluorouracil; Humans; Infusions, Parent

1991
Hemolytic-uremic syndrome and acute renal failure in metastatic adenocarcinoma treated with mitomycin: case report and literature review.
    Renal failure, 1987, Volume: 10, Issue:2

    Topics: Acute Kidney Injury; Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast N

1987
[A case of an exogastric developing-type carcinoma of the stomach and a review of thirty nine cases reported in Japan].
    Gan no rinsho. Japan journal of cancer clinics, 1988, Volume: 34, Issue:7

    Topics: Antigens, Neoplasm; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Chemotherapy P

1988

Trials

74 trials available for mitomycin and Metastase

ArticleYear
Chemotherapy, Irradiation, and Surgery for Function-preserving Curative Therapy of Primary Extremity Soft Tissue Sarcomas: Initial Treatment With I-MAP and Inhalation GM-CSF During Preoperative Irradiation and Postoperatively.
    American journal of clinical oncology, 2016, Volume: 39, Issue:2

    Topics: Administration, Inhalation; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin;

2016
Mitomycin C and capecitabine in pretreated patients with metastatic gastric cancer: a multicenter phase II study.
    Journal of cancer research and clinical oncology, 2014, Volume: 140, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycyti

2014
Mitomycin C and high-dose 5-fluorouracil with folinic acid as a therapeutic option for heavily pretreated patients with metastatic colorectal cancer: prospective phase II trial.
    The oncologist, 2014, Volume: 19, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Survival; D

2014
Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer.
    British journal of cancer, 2015, Jun-30, Volume: 113, Issue:1

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biom

2015
Mitomycin C plus S-1 as second-line therapy in patients with advanced gastric cancer: a noncomparative phase II study.
    Anti-cancer drugs, 2008, Volume: 19, Issue:3

    Topics: Adult; Aged; Anemia, Hemolytic; Antineoplastic Combined Chemotherapy Protocols; Disease Progression;

2008
Effect of multiple-phase regional intra-arterial infusion chemotherapy on patients with resectable pancreatic head adenocarcinoma.
    Chinese medical journal, 2009, Feb-05, Volume: 122, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine

2009
A phase II study of intra-arterial chemotherapy of 5-fluorouracil, cisplatin, and mitomycin C for advanced nonresectable gastric cancer.
    Anti-cancer drugs, 2009, Volume: 20, Issue:10

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin;

2009
Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jul-01, Volume: 28, Issue:19

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2010
Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jul-10, Volume: 28, Issue:20

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Com

2010
Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jul-10, Volume: 28, Issue:20

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Com

2010
Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jul-10, Volume: 28, Issue:20

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Com

2010
Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jul-10, Volume: 28, Issue:20

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Com

2010
Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jul-10, Volume: 28, Issue:20

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Com

2010
Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jul-10, Volume: 28, Issue:20

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Com

2010
Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jul-10, Volume: 28, Issue:20

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Com

2010
Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jul-10, Volume: 28, Issue:20

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Com

2010
Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jul-10, Volume: 28, Issue:20

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Com

2010
Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jul-10, Volume: 28, Issue:20

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Com

2010
Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jul-10, Volume: 28, Issue:20

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Com

2010
Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jul-10, Volume: 28, Issue:20

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Com

2010
Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jul-10, Volume: 28, Issue:20

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Com

2010
Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jul-10, Volume: 28, Issue:20

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Com

2010
Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jul-10, Volume: 28, Issue:20

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Com

2010
Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jul-10, Volume: 28, Issue:20

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Com

2010
Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jul-10, Volume: 28, Issue:20

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Com

2010
Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jul-10, Volume: 28, Issue:20

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Com

2010
Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jul-10, Volume: 28, Issue:20

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Com

2010
Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jul-10, Volume: 28, Issue:20

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Com

2010
Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jul-10, Volume: 28, Issue:20

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Com

2010
Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jul-10, Volume: 28, Issue:20

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Com

2010
Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jul-10, Volume: 28, Issue:20

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Com

2010
Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jul-10, Volume: 28, Issue:20

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Com

2010
Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jul-10, Volume: 28, Issue:20

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Com

2010
Combination of capecitabine and mitomycin C as first-line treatment in patients with metastatic breast cancer.
    Neoplasma, 2011, Volume: 58, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycy

2011
Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Dec-10, Volume: 30, Issue:35

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Chemoradiotherapy; Cisplatin;

2012
Folinic acid, 5-fluorouracil and mitomycin C in metastatic breast cancer patients previously treated with at least two chemotherapy regimens.
    Cancer chemotherapy and pharmacology, 2002, Volume: 50, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression;

2002
IPM chemotherapy in cytokine refractory renal cell cancer.
    British journal of cancer, 2003, May-19, Volume: 88, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Renal Cell; Ci

2003
[Clinical study on post-operative metastasis prevention of progressive stage of gastric cancer by weichang'an].
    Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine, 2003, Volume: 23, Issue:8

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drugs, Chinese Herbal; Female; F

2003
A phase II study of UFT and Leucovorin in combination with mitomycin C in patients with metastatic colorectal cancer.
    Acta oncologica (Stockholm, Sweden), 2004, Volume: 43, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Surv

2004
Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Oct-01, Volume: 22, Issue:19

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compound

2004
Mitomycin C, vinblastine and cisplatin (MVP): an active and well-tolerated salvage regimen for advanced breast cancer.
    British journal of cancer, 2005, Feb-14, Volume: 92, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Disease-Free Sur

2005
Phase II study of 5-fluorouracil, doxorubicin, and mitomycin C for metastatic small bowel adenocarcinoma.
    The oncologist, 2005, Volume: 10, Issue:2

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Duodenal Neoplas

2005
Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy coo
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Feb-20, Volume: 23, Issue:6

    Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Combined

2005
Capecitabine and mitomycin C is an effective combination for anthracycline- and taxane-resistant metastatic breast cancer.
    Oncology, 2006, Volume: 70, Issue:4

    Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deox

2006
Salvage chemotherapy with mitomycin C, ifosfamide, and cisplatin (MIC) for previously treated metastatic or recurrent esophageal squamous cell carcinoma.
    Investigational new drugs, 2008, Volume: 26, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di

2008
Phase II study of sequentially administered low-dose mitomycin-C (MMC) and irinotecan (CPT-11) in women with metastatic breast cancer (MBC).
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; DNA Top

2008
MIFA III (mitomycin-C, 5-fluorouracil, and adriamycin) chemotherapy for advanced adenocarcinoma of the pancreas.
    American journal of clinical oncology, 1984, Volume: 7, Issue:5

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Doxo

1984
Mitomycin C as an adjuvant in resected gastric cancer.
    Annals of surgery, 1983, Volume: 198, Issue:1

    Topics: Actuarial Analysis; Adult; Aged; Clinical Trials as Topic; Female; Follow-Up Studies; Gastrectomy; H

1983
Treatment of advanced breast cancer with two doxorubicin-containing regimens.
    American journal of clinical oncology, 1984, Volume: 7, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Doxorubi

1984
Mitomycin-C, etoposide, cisplatin, and hexamethylmelamine (MEPH) as a second-line regimen in lung cancer.
    American journal of clinical oncology, 1984, Volume: 7, Issue:5

    Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Cy

1984
A phase II study of Mitomycin C in refractory adcvanced breast cancer. A multi-centre pilot study.
    European journal of cancer, 1980, Volume: Suppl 1

    Topics: Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Mitomycin; Mitomycins; N

1980
Systemic mitomycin C as second-line treatment for metastatic urothelial cancer.
    Acta oncologica (Stockholm, Sweden), 1995, Volume: 34, Issue:7

    Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisp

1995
Combination chemotherapy with epirubicin and mitomycin C as first-line treatment in advanced breast cancer.
    European journal of cancer (Oxford, England : 1990), 1994, Volume: 30A, Issue:4

    Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administ

1994
Combination chemotherapy of 5-fluorouracil, epidoxorubicin and mitomycin C in the palliative treatment of locally advanced and/or metastatic adenocarcinoma of the stomach.
    Journal of chemotherapy (Florence, Italy), 1994, Volume: 6, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Epir

1994
Interim results on a randomized trial of mitomycin C in combination with orchidectomy for newly diagnosed metastatic prostate cancer.
    American journal of clinical oncology, 1995, Volume: 18, Issue:3

    Topics: Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Humans; Male; Middle Aged; Mitomycin; Neoplasm Meta

1995
Postoperative adjuvant hepatic arterial infusion of Lipiodol containing anticancer drugs in patients with hepatocellular carcinoma.
    Hepatology (Baltimore, Md.), 1994, Volume: 20, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization,

1994
Mitomycin C and mitoxantrone in anthracycline-pretreated advanced breast cancer patients. A phase II study.
    American journal of clinical oncology, 1994, Volume: 17, Issue:3

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neo

1994
[Multi-center cooperative phase II study of combined infusion of PJ-203 (degradable starch microspheres) into hepatic artery in metastatic liver cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1993, Volume: 20, Issue:13

    Topics: Adult; Aged; Embolization, Therapeutic; Female; Follow-Up Studies; Hepatic Artery; Humans; Injection

1993
[Comparative clinical study in metastatic liver cancer between intra-arterial infusion of mitomycin C alone and intra-arterial infusion of mitomycin C combined with PJ-203 (degradable starch microspheres)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1993, Volume: 20, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Embolization, Therapeutic; Female; Follow

1993
Chemotherapy with mitomycin C and vinblastine in pretreated metastatic breast cancer.
    Tumori, 1993, Aug-31, Volume: 79, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Middl

1993
Effective second line chemotherapy of advanced breast cancer with navelbine and mitomycin C.
    Breast cancer research and treatment, 1993, Volume: 26, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms

1993
A randomized trial of mitomycin-C (M) versus mitomycin-C plus high-dose medroxyprogesterone acetate (MMPA) in the treatment of patients with advanced breast cancer.
    American journal of clinical oncology, 1993, Volume: 16, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Medro

1993
[The chemoradiotherapy of advanced colorectal carcinoma--the results and toxicity in a pilot study with 44 patients].
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 1993, Volume: 169, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo

1993
Pharmacokinetics of BW12C and mitomycin C, given in combination in a phase 1 study in patients with advanced gastrointestinal cancer.
    Cancer chemotherapy and pharmacology, 1993, Volume: 32, Issue:1

    Topics: Benzaldehydes; Drug Combinations; Drug Evaluation; Gastrointestinal Neoplasms; Half-Life; Humans; Me

1993
MMM (mitomycin/mitoxantrone/methotrexate): an effective new regimen in the treatment of metastatic breast cancer.
    Oncology, 1993, Volume: 50 Suppl 1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosp

1993
Mitomycin C in combination with orchiectomy for newly diagnosed metastatic prostate cancer: preliminary results on a randomized trial.
    The Journal of urology, 1993, Volume: 149, Issue:6

    Topics: Aged; Combined Modality Therapy; Follow-Up Studies; Humans; Male; Mitomycin; Neoplasm Metastasis; Or

1993
Prophylactic filgrastim (G-CSF) during mitomycin-C, mitoxantrone, and methotrexate (MMM) treatment for metastatic breast cancer. A randomized study.
    American journal of clinical oncology, 1996, Volume: 19, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Filgrastim; G

1996
Postoperative adjuvant randomised trial comparing chemoendocrine therapy, chemotherapy and immunotherapy for patients with stage II breast cancer: 5-year results from the Nishinihon Cooperative Study Group of Adjuvant Chemoendocrine Therapy for Breast Can
    European journal of cancer (Oxford, England : 1990), 1996, Volume: 32A, Issue:2

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast

1996
[Therapy with mitomycin C, folic acid and 5-fluorouracil in treatment of metastatic, refractory urinary bladder carcinoma--phase II study].
    Der Urologe. Ausg. A, 1997, Volume: 36, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Drug Resistance,

1997
Mitomycin C and vinblastine in combination with amifostine in metastatic breast cancer. A feasibility study of the EORTC--Investigational Drug Branch for Breast Cancer (IDBBC).
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 1997, Volume: 5, Issue:5

    Topics: Adult; Aged; Amifostine; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplas

1997
A randomised trial of six versus twelve courses of chemotherapy in metastatic carcinoma of the breast.
    European journal of cancer (Oxford, England : 1990), 1997, Volume: 33, Issue:13

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dis

1997
Phase III studies of single-agent docetaxel in patients with metastatic breast cancer who have progressed despite previous chemotherapy regimens: preliminary results.
    Seminars in oncology, 1998, Volume: 25, Issue:6 Suppl 13

    Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Proto

1998
Induction with mitomycin C, doxorubicin, cisplatin and maintenance with weekly 5-fluorouracil, leucovorin for treatment of metastatic nasopharyngeal carcinoma: a phase II study.
    British journal of cancer, 1999, Volume: 80, Issue:12

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Doxorubicin

1999
[Polychemotherapy versus monotherapy in metastatic breast carcinoma].
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 1999, Volume: 175, Issue:9

    Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disea

1999
Mitomycin C continuous infusion as salvage chemotherapy in pretreated patients with advanced gastric cancer.
    Anti-cancer drugs, 1999, Volume: 10, Issue:8

    Topics: Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Humans; Infusion Pumps

1999
FEC (5-fluorouracil, epidoxorubicin and cyclophosphamide) versus EM (epidoxorubicin and mitomycin-C) with or without lonidamine as first-line treatment for advanced breast cancer. A multicentric randomised study. Final results.
    European journal of cancer (Oxford, England : 1990), 2000, Volume: 36, Issue:8

    Topics: Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophos

2000
Weekly 24-hour infusion of high-dose 5-fluorouracil plus folinic acid in combination with mitomycin C for the treatment of advanced gastric cancer.
    Oncology, 2000, Volume: 59, Issue:1

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Human

2000
Adjuvant intraportal chemotherapy for Dukes B2 and C colorectal cancer also receiving systemic treatment: results of a multicenter randomized trial. Groupe Régional d'Etude du Cancer Colo-Rectal (Belgium).
    Anti-cancer drugs, 2000, Volume: 11, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop

2000
Estrogen-receptor-directed neoadjuvant therapy for breast cancer: results of a randomised trial using formestane and methotrexate, mitozantrone and mitomycin C (MMM) chemotherapy.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:5

    Topics: Adult; Aged; Androstenedione; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic

2001
Locally advanced primary breast cancer: medium-term results of a randomised trial of multimodal therapy versus initial hormone therapy.
    European journal of cancer (Oxford, England : 1990), 2001, Volume: 37, Issue:18

    Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast

2001
Randomized phase II study of irinotecan plus mitomycin C vs. oxaliplatin plus mitomycin C in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer.
    Cancer investigation, 2002, Volume: 20, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta

2002
[A study of VMMC protocol (vindesine, mitoxantrone, mitomycin C) as a salvage chemotherapy in advanced breast cancers].
    Bulletin du cancer, 1992, Volume: 79, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relatio

1992
Mitomycin C + high-dose medroxyprogesterone versus cyclophosphamide+doxorubicin plus fluorouracil as first-line treatment for metastatic breast cancer.
    Oncology, 1992, Volume: 49, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dox

1992
A randomized trial comparing radiation therapy versus concomitant radiation therapy and chemotherapy in carcinoma of the thoracic esophagus.
    Cancer, 1991, May-01, Volume: 67, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Co

1991
Randomized, controlled study on adjuvant immunochemotherapy with PSK in curatively resected colorectal cancer. The Cooperative Study Group of Surgical Adjuvant Immunochemotherapy for Cancer of Colon and Rectum (Kanagawa).
    Diseases of the colon and rectum, 1992, Volume: 35, Issue:2

    Topics: Adjuvants, Immunologic; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemothera

1992
Randomised trial of epirubicin alone versus 5-fluorouracil, epirubicin and mitomycin C in locally advanced and metastatic carcinoma of the pancreas.
    British journal of cancer, 1991, Volume: 64, Issue:1

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Fluorouracil; Fol

1991
Phase II randomized trial of cisplatin chemotherapy regimens in the treatment of recurrent or metastatic squamous cell cancer of the cervix: a Southwest Oncology Group Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1987, Volume: 5, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci

1987
[Clinical effect of combined chemotherapy with UFT, MMC and OK-432 in recurring or advanced cancer of the digestive organs].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1989, Volume: 16, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Digestive System Neo

1989
Dose escalation and split course of 4-epidoxorubicin in combination chemotherapy (FEM II) of advanced gastric carcinoma. A phase-II trail of the 'Chemotherapiegruppe Gastrointestinaler Tumoren (CGT)'.
    Onkologie, 1989, Volume: 12, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Evaluat

1989
Vindesine and mitomycin C in metastatic breast cancer. A Southeastern Cancer Study Group Trial.
    Oncology, 1989, Volume: 46, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as To

1989
Treatment of advanced non-small cell lung cancer (NSCLC): the "Umbria" cooperative study.
    Seminars in oncology, 1988, Volume: 15, Issue:6 Suppl 7

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Eto

1988
Short-term chemotherapy of poor-prognosis metastatic breast cancer with three non-cross resistant chemotherapy regimens. A Southwest Oncology Group Study.
    Cancer, 1987, Jan-15, Volume: 59, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow; Breast Neoplasms; Clinical Trials as Topic; Cycloph

1987
Combined modality treatment of localized unresectable adenocarcinoma of the pancreas.
    International journal of radiation oncology, biology, physics, 1988, Volume: 14, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Clinical Trials as To

1988
A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1986, Volume: 4, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Cyclophos

1986
Trial of the combination of mitomycin, vindesine, and cisplatin in patients with advanced non-small cell lung cancer.
    Cancer treatment reports, 1986, Volume: 70, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Clinical Trials as Topic; Fema

1986
Extensive non-small cell lung cancer treated with mitomycin, cisplatin, and vindesine (MiPE): a Southwest Oncology Group Study.
    Cancer treatment reports, 1986, Volume: 70, Issue:9

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Clinical Trials as Topic

1986
Cyclophosphamide versus 5-fluorouracil, doxorubicin, and mitomycin C (FAM') in the treatment of hormone-resistant metastatic carcinoma of the prostate: a preliminary report of a randomized trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1985, Volume: 3, Issue:3

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin;

1985
Gastric cancer: overview of current therapies.
    Seminars in oncology, 1985, Volume: 12, Issue:3 Suppl 4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy;

1985

Other Studies

132 other studies available for mitomycin and Metastase

ArticleYear
Optimal perfusion chemotherapy: A prospective comparison of mitomycin C and oxaliplatin for hyperthermic intraperitoneal chemotherapy in metastatic colon cancer.
    Journal of surgical oncology, 2020, Volume: 121, Issue:8

    Topics: Antineoplastic Agents; Colonic Neoplasms; Combined Modality Therapy; Cytoreduction Surgical Procedur

2020
MTSS1 inhibits colorectal cancer metastasis by regulating the CXCR4/CXCL12 signaling axis.
    International journal of molecular medicine, 2021, Volume: 47, Issue:5

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Chemokine CXCL12; Cisplatin; Colorectal Neo

2021
[Regional chemotherapy in treatment of patients with unresectable liver metastases of uveal melanoma].
    Voprosy onkologii, 2016, Volume: 62, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoembolization, Therape

2016
Mitomycin-C and capecitabine (MIXE) as salvage treatment in patients with refractory metastatic colorectal cancer: a retrospective study.
    Anticancer research, 2013, Volume: 33, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytid

2013
ERCC1 expression does not predict survival and treatment response in advanced stage non-small cell lung cancer cases treated with platinum based chemotherapy.
    Asian Pacific journal of cancer prevention : APJCP, 2013, Volume: 14, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carb

2013
Non-randomized comparison between irinotecan plus mitomycin C and irinotecan alone in patients with advanced gastric cancer refractory to fluoropyrimidine and platinum.
    Anticancer research, 2013, Volume: 33, Issue:11

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptotheci

2013
[A case of gastric carcinosarcoma treated with surgical resection and irinotecan and mitomycin C combination therapy].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2014, Volume: 111, Issue:1

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy

2014
Efficacy and safety of raltitrexed combinations with uracil- tegafur or mitomycin C as salvage treatment in advanced colorectal cancer patients: a multicenter study of Anatolian Society of Medical Oncology (ASMO).
    Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:4

    Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto

2014
Metabolic alteration--Overcoming therapy resistance in gastric cancer via PGK-1 inhibition in a combined therapy with standard chemotherapeutics.
    International journal of surgery (London, England), 2015, Volume: 22

    Topics: Adenocarcinoma; Adenoviridae; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug

2015
Intensified intensity-modulated radiotherapy in anal cancer with prevalent HPV p16 positivity.
    World journal of gastroenterology, 2015, Oct-07, Volume: 21, Issue:37

    Topics: Adult; Aged; Aged, 80 and over; Anus Neoplasms; Carcinoma, Squamous Cell; Chemoradiotherapy; Cyclin-

2015
Mitomycin C and Capecitabine (MiX Trial) for Therapy of Patients with Metastasized, Breast Cancer Pretreated with Anthracycline.
    Anticancer research, 2016, Volume: 36, Issue:1

    Topics: Anthracyclines; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Breast Neoplasms; Cape

2016
Platinum-based chemotherapy in triple-negative breast cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:11

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy,

2008
Spontaneous transformation of human granulosa cell tumours into an aggressive phenotype: a metastasis model cell line.
    BMC cancer, 2008, Nov-04, Volume: 8

    Topics: Animals; Biomarkers, Tumor; Cell Growth Processes; Cell Line, Tumor; Disease Progression; Female; Gr

2008
Possible use of combination chemotherapy with mitomycin C and methotrexate for metastatic breast cancer pretreated with anthracycline and taxanes.
    Breast cancer (Tokyo, Japan), 2009, Volume: 16, Issue:4

    Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Femal

2009
Human umbilical cord blood mesenchymal stem cell-derived extracellular matrix prohibits metastatic cancer cell MDA-MB-231 proliferation.
    Cancer letters, 2010, Oct-28, Volume: 296, Issue:2

    Topics: Adult; Animals; Blotting, Western; Breast Neoplasms; Cell Culture Techniques; Cell Division; Extrace

2010
Anthracycline rechallenge using pegylated liposomal doxorubicin in patients with metastatic breast cancer: a pooled analysis using individual data from four prospective trials.
    British journal of cancer, 2010, Nov-09, Volume: 103, Issue:10

    Topics: Adolescent; Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemot

2010
Alterations of the retinoblastoma gene in metastatic breast cancer.
    Clinical & experimental metastasis, 2011, Volume: 28, Issue:3

    Topics: Adult; Anthracyclines; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Gene Expression Regulati

2011
Hypoxic liver perfusion with mitomycin-C for treating multifocal metastases and unresectable primary tumours: a single-centre series of 42 patients.
    La Radiologia medica, 2011, Volume: 116, Issue:8

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Cell Hypoxia; Disease-Free Survival; Feasibility Studies;

2011
Short-term effectiveness of radiochemoembolization for selected hepatic metastases with a combination protocol.
    World journal of gastroenterology, 2012, Oct-07, Volume: 18, Issue:37

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Chemoemboliz

2012
Matrix metalloproteinase inhibitor, marimastat, decreases peritoneal spread of gastric carcinoma in nude mice.
    Japanese journal of cancer research : Gann, 2002, Volume: 93, Issue:7

    Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Body Weight; Cell Survival; Coloring Ag

2002
Lung carcinoma with congenital plantar keratoderma as a variant of Clarke-Howel-Evans syndrome.
    International journal of dermatology, 2003, Volume: 42, Issue:6

    Topics: Adult; Antineoplastic Agents; Cisplatin; Drug Therapy, Combination; Fatal Outcome; Fluorouracil; Hum

2003
Ultralow doses of various drugs in chemotherapy of experimental tumors.
    Bulletin of experimental biology and medicine, 2003, Volume: 135 Suppl 7

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Resp

2003
CURRENT MANAGEMENT OF NEPHROBLASTOMA AND NEUROBLASTOMA.
    American journal of surgery, 1964, Volume: 107

    Topics: Antineoplastic Agents; Child; Dactinomycin; Fluorouracil; Infant; Infant, Newborn; Kidney Neoplasms;

1964
STUDIES ON REGIONAL PERFUSION AND INTRA-ARTERIAL INFUSION FOR CANCER CHEMOTHERAPY.
    Surgery, 1964, Volume: 55

    Topics: Antineoplastic Agents; Breast Neoplasms; Celiac Artery; Chemotherapy, Cancer, Regional Perfusion; Co

1964
[PREVENTION OF THE RECURRENCE OF CANCER].
    [Chiryo] [Therapy], 1964, Volume: 46

    Topics: Animals; Biomedical Research; Genetic Diseases, X-Linked; Hormones; Leukemia, Hairy Cell; Lymphatic

1964
[CHEMOTHERAPY OF PRIMARY AND METASTATIC HEPATIC CANCER BY HEPATIC ARTERY INFUSION].
    Gan no rinsho. Japan journal of cancer clinics, 1964, Volume: 10

    Topics: Blood; Hepatic Artery; Humans; Injections, Intra-Arterial; Liver Function Tests; Liver Neoplasms; Mi

1964
[METASTATIC LUNG TUMOR: CHARACTERISTICS OF THE X-RAY PICTURE AND THE TREATMENT OF CHOICE IN PRIMARY TUMORS].
    Gan no rinsho. Japan journal of cancer clinics, 1964, Volume: 10

    Topics: Antineoplastic Agents; Humans; Lung Neoplasms; Mitomycin; Neoplasm Metastasis; Neoplasms; Pneumonect

1964
CHEMOTHERAPY STUDIES ON PRIMARY TUMOR GRAFTS AND METASTASES IN HAMSTERS AND MICE.
    Acta - Unio Internationalis Contra Cancrum, 1964, Volume: 20

    Topics: Antineoplastic Agents; Cricetinae; Cyclophosphamide; Dactinomycin; Melphalan; Mice; Mitomycin; Mitom

1964
THE ADVERSE EFFECTS OF CANCER CHEMOTHERAPY.
    Acta - Unio Internationalis Contra Cancrum, 1964, Volume: 20

    Topics: Animals; Antineoplastic Agents; Azaguanine; Carcinoma, Ehrlich Tumor; Cortisone; Cyclophosphamide; D

1964
[EXPERIMENTAL STUDIES ON THE PREVENTION OF HEMATOGENIC METASTASIS OF CANCER WITH ANTICANCER DRUGS].
    Kumamoto Igakkai zasshi. The Journal of the Kumamoto Medical Society, 1964, Feb-25, Volume: 38

    Topics: Ascites; Blood Circulation; Injections, Intravenous; Liver Neoplasms; Mitomycin; Mitomycins; Neoplas

1964
INHIBITORY EFFECT OF ANTI-CANCER CHEMOTHERAPEUTICS ON LIVER METASTASIS OF INTRAPORTALLY INOCULATED MOUSE ASCITES HEPATOMA.
    The Tohoku journal of experimental medicine, 1964, Apr-25, Volume: 82

    Topics: Animals; Anti-Bacterial Agents; Antineoplastic Agents; Ascites; Carcinoma, Hepatocellular; Injection

1964
[EXPERIMENTAL STUDIES ON THE EFFECT OF ANTI-CANCER CHEMOTHERAPEUTICS TO LIVER METASTASIS FOLLOWING PORTAL INJECTION OF MOUSE ASCITES HEPATOMA].
    Tohoku igaku zasshi, 1963, Volume: 68

    Topics: Animals; Ascites; Carcinoma, Hepatocellular; Liver Neoplasms; Lung Neoplasms; Mice; Mitomycin; Mitom

1963
[DEVELOPMENT OF FREE-CELL SUBLINES OF THE ASCITES HEPATOMA AH-130 AND THEIR BIOLOGICAL PROPERTIES].
    Gan, 1964, Volume: 55

    Topics: Ascites; Carcinoma, Hepatocellular; Chromosomes; Electrons; Liver Neoplasms; Mechlorethamine; Micros

1964
Erythropoietin modulates the anticancer activity of chemotherapeutic drugs in a murine lung cancer model.
    Cancer letters, 2004, Oct-28, Volume: 214, Issue:2

    Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Lewis Lung; Cisplatin; C

2004
Prognostic factors in cytokine-refractory renal cell carcinoma treated with irinotecan, Cisplatin, and mitomycin chemotherapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Feb-20, Volume: 23, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Renal Cell; Cisplatin; Cyto

2005
A new survival model for hyperthermic intraperitoneal chemotherapy (HIPEC) in tumor-bearing rats in the treatment of peritoneal carcinomatosis.
    BMC cancer, 2005, May-30, Volume: 5

    Topics: Animals; Body Weight; Cell Line, Tumor; Combined Modality Therapy; Dose-Response Relationship, Drug;

2005
Increased dosage of epirubicin and mitomycin-C for the treatment of metastatic adenocarcinoma of unknown primary site.
    Journal of chemotherapy (Florence, Italy), 1989, Volume: 1, Issue:4 Suppl

    Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Biopsy; Dose-Response Relationship, Drug; Epirubicin; H

1989
Second and third line chemotherapy in advanced breast cancer.
    Journal of chemotherapy (Florence, Italy), 1989, Volume: 1, Issue:4 Suppl

    Topics: Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Sche

1989
Capecitabine and mitomycin C in patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan.
    British journal of cancer, 2006, Mar-27, Volume: 94, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; F

2006
[Comparing cisplatin plus etoposide with combination of mitomycin, ifosfamide and cisplatin in advanced non-small cell lung cancer patients].
    Tuberkuloz ve toraks, 2006, Volume: 54, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide

2006
Inhibition of tumor implantation after laparoscopy by specific oligopeptides: a novel approach to adjuvant intraperitoneal therapy to prevent tumor implantation in an animal model.
    European urology, 2007, Volume: 52, Issue:2

    Topics: Analysis of Variance; Animals; Chi-Square Distribution; Female; Injections, Intraperitoneal; Laparos

2007
p53 targets identified by protein expression profiling.
    Proceedings of the National Academy of Sciences of the United States of America, 2007, Mar-27, Volume: 104, Issue:13

    Topics: Apoptosis; Cell Line, Tumor; Colonic Neoplasms; Electrophoresis, Gel, Two-Dimensional; Gene Expressi

2007
The present article describes decreased intraperitoneal urothelial tumor cell growth by administration of antiadhesive oligopeptides or mitomycin.
    European urology, 2007, Volume: 52, Issue:2

    Topics: Animals; Female; Injections, Intraperitoneal; Laparoscopy; Mice; Mice, Inbred C57BL; Mitomycin; Mode

2007
UFT/leucovorin and mitomycin C as salvage treatment in patients with advanced colorectal cancer - a retrospective analysis.
    Anti-cancer drugs, 2007, Volume: 18, Issue:6

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colonic Neo

2007
Response to a third-line mitomycin C (MMC)-based chemotherapy in a patient with metastatic pancreatic adenocarcinoma carrying germline BRCA2 mutation.
    JOP : Journal of the pancreas, 2008, May-08, Volume: 9, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Female; Genes, BRCA

2008
Hepatic arterial chemotherapy and occlusion for palliation of primary hepatocellular and unknown primary neoplasms in the liver.
    Cancer, 1983, Apr-15, Volume: 51, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Doxorubicin;

1983
Comparison of drug sensitivity among tumor cells within a tumor, between primary tumor and metastases, and between different metastases in the human tumor colony-forming assay.
    Cancer research, 1984, Volume: 44, Issue:6

    Topics: Antineoplastic Agents; Bleomycin; Cell Division; Cell Survival; Cells, Cultured; Cisplatin; Doxorubi

1984
Mitomycin C, melphalan and methotrexate combination chemotherapy for palliation of disseminated breast cancer.
    Cancer chemotherapy and pharmacology, 1984, Volume: 13, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Evaluation; Fema

1984
Adenoid cystic carcinoma of the salivary gland. Sustained complete response to chemotherapy.
    Cancer, 1983, Feb-15, Volume: 51, Issue:4

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenoid Cystic; Doxorubicin; Drug

1983
[Comparison between continuous arterial infusion chemotherapy and mitomycin C microcapsule administration in primary and metastatic liver cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1983, Volume: 10, Issue:4 Pt 2

    Topics: Antibiotics, Antineoplastic; Breast Neoplasms; Capsules; Carcinoma, Hepatocellular; Hepatic Artery;

1983
Combined modality therapy for esophageal squamous cell carcinoma.
    Cancer, 1983, Mar-15, Volume: 51, Issue:6

    Topics: Abdomen; Adult; Aged; Carcinoma, Squamous Cell; Drug Therapy, Combination; Esophageal Neoplasms; Eso

1983
Methotrexate and mitomycin for patients with metastatic transitional cell carcinoma of the urinary tract.
    Cancer treatment reports, 1983, Volume: 67, Issue:5

    Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Drug Evaluation; Drug Therapy, Combination; Hum

1983
Reversible microangiopathic hemolytic anemia after mitomycin C.
    Cancer chemotherapy and pharmacology, 1983, Volume: 10, Issue:3

    Topics: Adenocarcinoma; Aged; Anemia, Hemolytic; Antibiotics, Antineoplastic; Humans; Male; Mitomycin; Mitom

1983
[Chemotherapy of gastric cancer patients with hepatic metastases].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1983, Volume: 10, Issue:2 Pt

    Topics: Administration, Oral; Antibiotics, Antineoplastic; Fluorouracil; Humans; Liver Neoplasms; Mitomycin;

1983
[Combination chemotherapy with mitomycin C, methotrexate, and vincristine (MMV) for metastatic breast cancer refractory to adriamycin].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1983, Volume: 10, Issue:3

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Breast Neoplasms; Doxorubicin; Drug Resistance; Drug Thera

1983
[Treatment of metastasizing prostatic carcinoma with DMF. Presentation of a prospective study].
    Der Urologe. Ausg. A, 1983, Volume: 22 Suppl

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Fluorouracil; Humans; M

1983
[Analysis of the mechanism of cancer metastasis by using anticancer agents].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1984, Volume: 11, Issue:2

    Topics: Animals; Antineoplastic Agents; Cell Division; Cisplatin; Killer Cells, Natural; Liver Neoplasms; Ma

1984
Combination chemotherapy with BCNU, vincristine, mitomycin-C and prednisone in refractory breast carcinoma. A pilot study.
    Oncology, 1984, Volume: 41, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carmu

1984
Treatment of metastatic colorectal carcinoma with 5-FU, mitomycin, vincristine, and methotrexate.
    Cancer treatment reports, 1984, Volume: 68, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Evaluation; Fem

1984
[Antitumor effect of new lymphokine OH-1 on BDF1 mice bearing Lewis lung carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1984, Volume: 11, Issue:6

    Topics: Animals; Cyclophosphamide; Doxorubicin; Female; Lung Neoplasms; Lymphokines; Mice; Mitomycin; Mitomy

1984
[The injurious effect of granulocytes and mitomycin C added to cultured human vascular endothelium].
    Nihon geka hokan. Archiv fur japanische Chirurgie, 1983, Nov-01, Volume: 52, Issue:6

    Topics: Antibiotics, Antineoplastic; Blood Vessels; Cell Adhesion; Cells, Cultured; Endopeptidases; Endothel

1983
Regional intra-arterial mitomycin C infusion in previously treated patients with metastatic colorectal cancer and concomitant measurement of serum drug level.
    Cancer treatment reports, 1984, Volume: 68, Issue:11

    Topics: Adenocarcinoma; Aged; Bone Marrow; Colonic Neoplasms; Female; Humans; Infusions, Intra-Arterial; Mal

1984
Adoptive immune therapy in mice bearing poorly immunogenic metastases, using T lymphocytes stimulated in vitro against highly immunogenic mutant sublines.
    International journal of cancer, 1984, Nov-15, Volume: 34, Issue:5

    Topics: Animals; Antibiotics, Antineoplastic; Immunization, Passive; Immunotherapy; Mice; Mice, Inbred DBA;

1984
A retrospective study of FAM regimen in 38 patients with advanced gastric cancer.
    Tumori, 1984, Aug-31, Volume: 70, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Fluorouracil; Humans; Midd

1984
Treatment of hormone-resistant metastatic carcinoma of the prostate with 5-FU, doxorubicin, and mitomycin (FAM'): a preliminary report.
    Cancer treatment reports, 1983, Volume: 67, Issue:10

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Fluorouracil; Humans; Male; Middl

1983
Mitomycin C and vinblastine chemotherapy for advanced breast cancer.
    Cancer, 1981, Sep-15, Volume: 48, Issue:6

    Topics: Adult; Aged; Breast Neoplasms; Drug Therapy, Combination; Female; Humans; Middle Aged; Mitomycin; Mi

1981
Efficacy of dacarbazine imidazole carboxamide and mitomycin C combination therapy in patients with adenocarcinoma of the colon refractory to 5-fluorouracil therapy.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 1981, Volume: 79

    Topics: Adenocarcinoma; Colonic Neoplasms; Dacarbazine; Drug Resistance; Drug Therapy, Combination; Female;

1981
[Effect of cancer chemotherapy for unresectable cancer of the pancreas].
    Nihon Gan Chiryo Gakkai shi, 1982, Oct-20, Volume: 17, Issue:7

    Topics: Antineoplastic Agents; Drug Therapy, Combination; Female; Fluorouracil; Humans; Liver Neoplasms; Mal

1982
[Antitumor treatment for synchronous hepatic metastasis from stomach cancer].
    Nihon Gan Chiryo Gakkai shi, 1982, Oct-20, Volume: 17, Issue:7

    Topics: Adult; Aged; Antineoplastic Agents; Drug Therapy, Combination; Female; Fluorouracil; Humans; Liver N

1982
Vincristine, adriamycin, and mitomycin (VAM) therapy for previously treated breast cancer. A preliminary report.
    Cancer, 1983, Jan-15, Volume: 51, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms

1983
Anticancer chemosensitivity changes between the original and recurrent tumors after successful chemotherapy selected according to the sensitivity assay.
    Annals of surgery, 1995, Volume: 221, Issue:1

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; DNA, Neoplasm; Dox

1995
A novel "patient-like" treatment model of human pancreatic cancer constructed using orthotopic transplantation of histologically intact human tumor tissue in nude mice.
    Cancer research, 1993, Jul-01, Volume: 53, Issue:13

    Topics: Animals; Disease Models, Animal; Drug Screening Assays, Antitumor; Fluorouracil; Humans; Liver Neopl

1993
Chemoradiotherapy versus radiotherapy alone for anal cancer: a retrospective comparison.
    International journal of radiation oncology, biology, physics, 1993, Sep-01, Volume: 27, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Anus Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Fol

1993
[Importance of systemic administration of pyrimidine after thermochemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1993, Volume: 20, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Fluorouracil; Gas

1993
Antimetastatic effect by anti-adhesion therapy with cell-adhesive peptide of fibronectin in combination with anticancer drugs.
    Japanese journal of cancer research : Gann, 1993, Volume: 84, Issue:3

    Topics: Amino Acid Sequence; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Adhesion; Dose-Re

1993
An aggressive therapeutic approach to carcinoma of the body and tail of the pancreas.
    Cancer, 1996, Jun-01, Volume: 77, Issue:11

    Topics: Adenocarcinoma; Adrenal Gland Neoplasms; Adrenalectomy; Adult; Aged; Combined Modality Therapy; Duod

1996
Patterns of failure following treatment of pseudomyxoma peritonei of appendiceal origin.
    European journal of cancer (Oxford, England : 1990), 1996, Volume: 32A, Issue:10

    Topics: Abdomen; Adult; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Chemotherapy,

1996
Improved mortality rate of gastric carcinoma patients with peritoneal carcinomatosis treated with intraperitoneal hyperthermic chemoperfusion combined with surgery.
    Cancer, 1997, Mar-01, Volume: 79, Issue:5

    Topics: Carcinoma; Combined Modality Therapy; Female; Humans; Hyperthermia, Induced; Male; Middle Aged; Mito

1997
"Sandwich" preoperative and postoperative combined chemotherapy and radiation in tethered and fixed rectal cancer: impact of treatment intensity on local control and survival.
    International journal of radiation oncology, biology, physics, 1997, Feb-01, Volume: 37, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Combined Mod

1997
Immunosuppression by metastatic lymphoma derived altered retroviral gp70 molecule.
    Leukemia, 1997, Volume: 11 Suppl 3

    Topics: Abelson murine leukemia virus; Animals; Cell Line; Cell Transformation, Neoplastic; Gene Products, e

1997
[Therapeutic effect of matrix metalloproteinase inhibitor (R-94138) for peritoneal metastasis of stomach neoplasm models].
    Nihon Geka Gakkai zasshi, 1997, Volume: 98, Issue:9

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Models, Animal; Injectio

1997
Preventive effect of matrix metalloproteinase inhibitor, R-94138, in combination with mitomycin C or cisplatin on peritoneal dissemination of human gastric cancer cell line TMK-1 in nude mice.
    Japanese journal of cancer research : Gann, 1999, Volume: 90, Issue:1

    Topics: Acetamides; Animals; Antineoplastic Agents; Cisplatin; Gelatinases; Humans; Male; Matrix Metalloprot

1999
Chemosensitivity of advanced larynx carcinoma cells in vitro and significance of multidrug resistance markers in these tumors.
    Cancer biotherapy & radiopharmaceuticals, 1998, Volume: 13, Issue:2

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biomarkers, Tumor; C

1998
The role of mitomycin C in the treatment of patients with advanced colorectal cancer resistant to 5-fluorouracil-folinic acid chemotherapy.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:4

    Topics: Antibiotics, Antineoplastic; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Humans;

2001
A cost--utility analysis comparing second-line chemotherapy schemes in patients with metastatic breast cancer.
    Anti-cancer drugs, 2001, Volume: 12, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms

2001
Lactosaminated and intact N-succinyl-chitosans as drug carriers in liver metastasis.
    International journal of pharmaceutics, 2001, Sep-11, Volume: 226, Issue:1-2

    Topics: Animals; Area Under Curve; Chitin; Chitosan; Drug Carriers; Injections, Intravenous; Lactose; Liver

2001
[Concomitant radiochemotherapy for non-small-cell lung cancer: towards an ideal strategy].
    Revue des maladies respiratoires, 2001, Volume: 18, Issue:4 Pt 1

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineopl

2001
[Adenocarcinomas of the distal esophagus and gastric cardia: what chemotherapy or chemoradiotherapy for recurrent or metastatic disease?].
    Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2001, Volume: 5 Suppl 1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cardia; Cisplatin; Combined Modality

2001
[Combination therapy including mutamycin (mitomycin C) in the treatment of advanced colorectal and gastric cancer].
    Voprosy onkologii, 2001, Volume: 47, Issue:6

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; An

2001
Efficacy of lactosaminated and intact N-succinylchitosan-mitomycin C conjugates against M5076 liver metastatic cancer.
    The Journal of pharmacy and pharmacology, 2002, Volume: 54, Issue:4

    Topics: Amino Sugars; Animals; Area Under Curve; Chitin; Chitosan; Drug Administration Schedule; Fluorescein

2002
Combination chemotherapy with cisplatin, vindesine and mitomycin-C for advanced, inoperable non-small-cell lung cancer.
    The Medical journal of Australia, 1992, May-18, Volume: 156, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat

1992
[Trend and problems of chemotherapy of stomach neoplasms with metastasis].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 1992, May-10, Volume: 81, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Humans; Mitomycin; Neoplasm

1992
Promotion of hepatic metastases by liver resection in the rat.
    British journal of cancer, 1992, Volume: 65, Issue:6

    Topics: Animals; Fluorouracil; Liver; Liver Neoplasms; Liver Neoplasms, Experimental; Liver Regeneration; Mi

1992
Combination therapy of radiation and Sizofiran (SPG) on the tumor growth and metastasis on squamous-cell carcinoma NR-S1 in syngeneic C3H/He mice.
    Biotherapy (Dordrecht, Netherlands), 1992, Volume: 4, Issue:2

    Topics: Animals; Carcinoma, Squamous Cell; Combined Modality Therapy; Immunotherapy; Lung Neoplasms; Male; M

1992
Combination chemotherapy with mitomycin C, vindesine and melphalan for refractory metastatic breast cancer.
    Journal of cancer research and clinical oncology, 1991, Volume: 117, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Melph

1991
[A clinical study on renal cell carcinoma].
    Hinyokika kiyo. Acta urologica Japonica, 1991, Volume: 37, Issue:10

    Topics: Carcinoma, Renal Cell; Female; Humans; Interferon-alpha; Kidney Neoplasms; Lymphatic Metastasis; Mal

1991
[A clinical study of vitamin A concerning auxiliary chemotherapies after operation of gastric cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1991, Volume: 18, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Gastrectomy; Humans; Lymphatic

1991
Alternating chemotherapy in advanced gastric cancer. A phase II study.
    Cancer chemotherapy and pharmacology, 1991, Volume: 28, Issue:4

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Doxoru

1991
[The usefulness of UFT administration in colorectal cancer with emphasis on postoperative administration (Part 3)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1991, Volume: 18, Issue:14

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combine

1991
A phase II trial of mitomycin C and 5-fluorouracil as second-line therapy in advanced breast cancer.
    Cancer chemotherapy and pharmacology, 1990, Volume: 27, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Evaluation; Fluo

1990
Combination chemotherapy for patients with advanced carcinoma of the cervix: trial of mitomycin-C, vincristine, bleomycin, and cisplatin.
    Gynecologic oncology, 1987, Volume: 26, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Female; Follow-Up

1987
Nonoperative therapy for squamous-cell cancer of the esophagus.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1987, Volume: 5, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin

1987
Chemotherapy for advanced and/or recurrent cervical cancer.
    Archives of gynecology, 1987, Volume: 240, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci

1987
Epidermoid carcinoma of the anal canal. Results of treatment by combined chemotherapy and radiation therapy.
    Diseases of the colon and rectum, 1989, Volume: 32, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc

1989
[Surgery for far-advanced colorectal cancer--extension of surgical indication and its results].
    Nihon Geka Gakkai zasshi, 1989, Volume: 90, Issue:9

    Topics: Colorectal Neoplasms; Combined Modality Therapy; Humans; Mitomycin; Mitomycins; Neoplasm Metastasis;

1989
Primary treatment of regional and disseminated pancreatic cancer with hexamethylmelamine, mitomycin C and 5-fluorouracil infusion.
    Oncology, 1989, Volume: 46, Issue:6

    Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Fluorouracil; Humans; Infusi

1989
Etoposide and mitomycin-C in pretreated metastatic breast cancer.
    Tumori, 1989, Oct-31, Volume: 75, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Etopo

1989
[Systemically administered regional tumor therapy. Regional hemi-body chemotherapy of metastatic malignant melanoma--an experimental therapy concept].
    Onkologie, 1989, Volume: 12, Issue:6

    Topics: Adult; Antineoplastic Agents; Catheters, Indwelling; Chemotherapy, Cancer, Regional Perfusion; Cispl

1989
[Prolonged remissions induced by the combination vindesine, mitoxantrone, mitomycine C in metastatic breast cancers].
    Presse medicale (Paris, France : 1983), 1987, Apr-11, Volume: 16, Issue:13

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Middl

1987
Vindesine and mitomycin C in chemotherapy: refractory advanced breast cancer.
    Cancer, 1986, Mar-01, Volume: 57, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Leuko

1986
[A case of bilateral metastatic breast carcinoma from gastric carcinoma].
    Gan no rinsho. Japan journal of cancer clinics, 1986, Volume: 32, Issue:4

    Topics: Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined

1986
Phase II study of the three-drug combination of mitomycin C, CCNU, and methotrexate (MCM) in advanced non-small cell lung cancer.
    American journal of clinical oncology, 1986, Volume: 9, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Female; Humans; Lomust

1986
An aggressive, sequential combination chemotherapy regimen in the treatment of metastatic colorectal carcinoma.
    Progress in clinical and biological research, 1986, Volume: 216

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Dose-Response Relati

1986
Superficial bladder cancer: intravesical chemotherapy and tumour progression to muscle invasion or metastases.
    British journal of urology, 1986, Volume: 58, Issue:6

    Topics: Administration, Intravesical; Carcinoma, Transitional Cell; Ethoglucid; Humans; Methotrexate; Mitomy

1986
Phase II clinical trial of triazinate in combination with mitomycin C for patients with advanced gastric cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1987, Volume: 5, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Female; Human

1987
[Metastasizing primary duodenal cancer. Extended remission in a patient following chemotherapy].
    Onkologie, 1986, Volume: 9, Issue:5

    Topics: Adenocarcinoma, Papillary; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality T

1986
Mitomycin C pharmacokinetics in patients with recurrent or metastatic colorectal carcinoma.
    Canadian journal of physiology and pharmacology, 1987, Volume: 65, Issue:3

    Topics: Aged; Chromatography, High Pressure Liquid; Colonic Neoplasms; Half-Life; Humans; Kidney; Kinetics;

1987
5-Fluorouracil, 4-epidoxorubicin, and mitomycin C (FEM) combination chemotherapy for advanced gastric carcinoma. A phase-II trial by the "chemotherapiegruppe gastrointestinaler tumoren (CGT)".
    Onkologie, 1987, Volume: 10, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Doxorubicin; Drug E

1987
Cyclophosphamide, methotrexate,5-fluorouracil, alternating with adriamycin and mitomycin C in metastatic breast cancer: a pilot study.
    Tumori, 1987, Jun-30, Volume: 73, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Doxorubici

1987
Mitomycin C is an inactive drug in the third-line treatment of hormone and chemotherapy refractory breast cancer.
    European journal of cancer & clinical oncology, 1987, Volume: 23, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Fe

1987
A novel antitumor cyclic hexapeptide (RA-700) obtained from Rubiae radix.
    Journal of pharmacobio-dynamics, 1987, Volume: 10, Issue:11

    Topics: Animals; Antineoplastic Agents, Phytogenic; Doxorubicin; Drug Evaluation, Preclinical; Female; Leuke

1987
[Chemotherapy and enteral nutrition in stomach cancer].
    Infusionstherapie (Basel, Switzerland), 1988, Volume: 15, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy;

1988
Spontaneous sister chromatid exchange in metastatic variants of the murine B16 melanoma and human astrocytomas in culture.
    Invasion & metastasis, 1988, Volume: 8, Issue:4

    Topics: Animals; Astrocytoma; Ethyl Methanesulfonate; Humans; Melanoma, Experimental; Mice; Mitomycin; Mitom

1988
[Sequential treatment of progressive metastatic colorectal cancer with 5-fluorouracil/folinic acid, dipyramidole and mitomycin C].
    Onkologie, 1988, Volume: 11 Suppl 2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dipyridamole; Dos

1988
Long-term survivors in metastatic non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1986, Volume: 4, Issue:5

    Topics: Adenocarcinoma; Aged; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Body Wei

1986
Chemotherapy of advanced gastric cancer: a study of 43 consecutive cases treated with fluorouracil, adriamycin and mitomycin C (FAM).
    Chemioterapia : international journal of the Mediterranean Society of Chemotherapy, 1986, Volume: 5, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Fluorouracil; Huma

1986
Effects of total-body hyperthermia on metastases from experimental mouse tumors.
    Cancer research, 1985, Volume: 45, Issue:4

    Topics: Animals; Cisplatin; Hyperthermia, Induced; Lung Neoplasms; Lymphatic Metastasis; Male; Mice; Mice, I

1985
Possible enhancement of the cardiotoxicity of doxorubicin when combined with mitomycin C.
    Medical oncology and tumor pharmacotherapy, 1985, Volume: 2, Issue:2

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neo

1985
Melphalan-induced enhancement of tumor cell immunostimulatory capacity as a mechanism for the appearance of potent antitumor immunity in the spleen of mice bearing a large metastatic MOPC-315 tumor.
    Cancer immunology, immunotherapy : CII, 1985, Volume: 20, Issue:1

    Topics: Animals; Cell Division; Cytotoxicity, Immunologic; Immunity, Cellular; Melphalan; Mice; Mitomycin; M

1985
[Experiences with polychemotherapy MAF (mitomycin C, adriablastine, 5-fluorouracil) in progressing metastasized prostate cancer].
    Helvetica chirurgica acta, 1985, Volume: 52, Issue:3-4

    Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Fluorourac

1985
Mitomycin C and vinblastine in the treatment of advanced breast cancer.
    European journal of cancer & clinical oncology, 1985, Volume: 21, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Middl

1985
[A combination chemotherapy using mitomycin C, vincristine and cisplatin (MVP) for advanced cervical cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1985, Volume: 12, Issue:3 Pt 1

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug

1985